Leads having sidewall openings, and associated systems and methods

Information

  • Patent Grant
  • 11420045
  • Patent Number
    11,420,045
  • Date Filed
    Thursday, March 28, 2019
    5 years ago
  • Date Issued
    Tuesday, August 23, 2022
    a year ago
Abstract
The present technology is generally directed to spinal cord modulation leads having one or more sidewall openings configured for inserting stylets to steer and/or position the leads within a patient and/or with respect to a pulse generator, and associated systems and methods. In some embodiments, sidewall opening is generally positioned in an intermediate portion of the lead and is operatively coupled to a lumen extending distally to a distal end of the lead, and/or proximally to a proximal end of the lead.
Description
TECHNICAL FIELD

The present technology is directed generally to leads having sidewall openings for receiving stylets, e.g., to steer and position the leads within a patient and/or with respect to a pulse generator, and associated systems and methods.


BACKGROUND

Neurological stimulators have been developed to treat pain, movement disorders, functional disorders, spasticity, cancer, cardiac disorders, and various other medical conditions. Implantable neurological stimulation systems generally have an implantable pulse generator and one or more leads that deliver electrical pulses to neurological tissue or muscle tissue. For example, several neurological stimulation systems for spinal cord stimulation (SCS) have cylindrical leads that include a lead body with a circular cross-sectional shape and multiple conductive rings spaced apart from each other at the distal end of the lead body. The conductive rings operate as individual electrodes or contacts and the SCS leads are typically implanted either surgically or externally through a needle inserted into the epidural space, often with the assistance of a stylet.


Once implanted, the pulse generator applies electrical pulses to the electrodes, which in turn modify the function of the patient's nervous system, such as by altering the patient's responsiveness to sensory stimuli and/or altering the patient's motor-circuit output. The electrical pulses can generate sensations that mask or otherwise alter the patient's sensation of pain. For example, in many cases, patients report a tingling or paresthesia that is perceived as more pleasant and/or less uncomfortable than the underlying pain sensation. In other cases, the patients can receive pain relief without paresthesia or other sensations.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a partially schematic illustration of an implantable spinal cord modulation system positioned at the spine to deliver therapeutic signals in accordance with some embodiments of the present technology.



FIG. 1B is a partially schematic, cross-sectional illustration of a patient's spine, illustrating representative locations for implanted lead bodies in accordance with some embodiments of the present technology.



FIG. 2A is a partially schematic side view illustration of a lead configured in accordance with some embodiments of the present technology.



FIG. 2B is a partially schematic side view illustration of a portion of a representative lead having a lumen with an opening and a corresponding seal configured in accordance with embodiments of the present technology.



FIG. 3A is a partially schematic cross-sectional illustration of the lead of FIG. 2A taken generally along line 3A-3A.



FIGS. 3B-3D are partially schematic cross-sectional illustrations of other leads configured in accordance with some embodiments of the present technology.



FIG. 4 is a partially schematic side view illustration of a lead configured in accordance with some embodiments of the present technology.



FIG. 5 is a cross-sectional illustration of a lead configured in accordance with some embodiments of the present technology.



FIGS. 6A-6D are partially schematic illustrations of lead proximal portions having lumens accessible via openings for one or more stylets, in accordance with embodiments of the present technology.





DETAILED DESCRIPTION

The present technology is directed generally to leads having a sidewall with one or more openings (e.g., sidewall openings) and associated systems and methods. In some embodiments, the leads are implantable leads. In some embodiments, the implantable leads are modulation leads. For example, the modulation leads can be spinal cord stimulation (SCS) leads, deep brain stimulation (DBS) leads, peripheral nerve stimulation (PNS) leads, and/or sacral (e.g., non-spinal cord region, such as horsetail region) stimulation leads. In some embodiments, the leads are percutaneous leads. In at least some contexts, the leads include a lumen extending from the sidewall opening to a distal portion of the lead. The lumen can be configured to receive a stylet shaped and sized to be removably inserted into the lumen through the opening. The lead can further include a proximal portion, and an intermediate portion disposed between the distal portion and the proximal portion. Together, the intermediate portion and the distal portion comprise a steerable portion of the lead. Leads configured in accordance with the present technology can have improved steering by virtue of one or more openings disposed in the intermediate portion of the lead. As a result, longer leads can be steered similarly to shorter leads. Furthermore, leads configured in accordance with the present technology can reduce the duration of a procedure associated with inserting and/or positioning a lead, and/or can increase the accuracy and/or the efficiency of these procedures.


In other embodiments, the lumen can extend from the sidewall opening (located at the intermediate portion of a lead) to a proximal end of the lead. Accordingly, the stylet can provide support to the proximal portion of the lead. The practitioner can use this arrangement to improve the ease and accuracy with which the proximal portion of the lead is inserted into a pulse generator or other device that provides electrical or other communication with the distal end of the lead. As will be described in further detail below, whether the sidewall opening or openings facilitate support of the distal end of the lead and/or the proximal end of the lead, the opening(s) can improve the efficiency, accuracy, and/or repeatability of insertion processes performed with the lead.


Specific details of some embodiments of the present technology are described below with reference to representative spinal cord modulation leads to provide a thorough understanding of these embodiments, but some embodiments can have other arrangements. Several details describing structures or processes that are well-known and often associated with leads and associated devices but that may unnecessarily obscure some significant aspects of the disclosure are not set forth in the following description for purposes of clarity. Moreover, although the following disclosure sets forth some embodiments of different aspects of the technology, some embodiments of the technology can have different configurations, different components, and/or different procedures than those described below. Some embodiments may eliminate particular components and/or procedures. A person of ordinary skill in the relevant art, therefore, will understand that the present technology which includes associated devices, systems, and procedures, may include some embodiments with additional elements or steps, and/or may include some embodiments without several of the features or steps shown and described below with reference to FIGS. 1A-6D. Several aspects of overall systems in accordance with the disclosed technology are described with reference to FIGS. 1A and 1B, and features specific to leads having sidewall openings are then discussed with reference to FIGS. 2A-6D.


1.0 Overview


FIG. 1A schematically illustrates a representative patient therapy system 100 for providing relief from chronic pain and/or other conditions, arranged relative to the general anatomy of a patient's spinal column 191. While system 100 is illustrated as an SCS system, the system 100 can also be configured for DBS, PNS, sacral stimulation, and/or other types of stimulation involving leads, such as implantable leads or percutaneous leads. The system 100 can include a signal generator 101 (e.g., an implanted or implantable pulse generator or IPG), which may be implanted subcutaneously within a patient 190 and coupled to one or more signal delivery elements or devices 110. The signal delivery elements or devices 110 may be implanted within the patient 190, typically at or near the patient's spinal cord midline 189. The signal delivery elements 110 carry features for delivering therapy to the patient 190 after implantation. The signal generator 101 can be connected directly to the signal delivery devices 110, or it can be coupled to the signal delivery devices 110 via a signal link, e.g., a lead extension 102. In some embodiments, the signal delivery devices 110 can include one or more elongated lead(s) or lead body or bodies 111 (identified individually as a first lead 111a and a second lead 111b). As used herein, the terms “signal delivery device,” “lead,” and/or “lead body” include any of a number of suitable substrates and/or supporting members that carry electrodes/devices for providing therapy signals to the patient 190. For example, the lead or leads 111 can include one or more electrodes or electrical contacts that direct electrical signals into the patient's tissue, e.g., to provide for therapeutic relief. In some embodiments, the signal delivery elements 110 can include structures other than a lead body (e.g., a paddle) that also direct electrical signals and/or other types of signals to the patient 190, e.g., as disclosed in U.S. Patent Application Publication No. 2018/0256892, which is incorporated herein by reference in its entirety.


In some embodiments, one signal delivery device may be implanted on one side of the spinal cord midline 189, and a second signal delivery device may be implanted on the other side of the spinal cord midline 189. For example, the first and second leads 111a, 111b shown in FIG. 1A may be positioned just off the spinal cord midline 189 (e.g., about 1 mm offset) in opposing lateral directions so that the two leads 111a, 111b are spaced apart from each other by about 2 mm. In some embodiments, the leads 111 may be implanted at a vertebral level ranging from, for example, about T8 to about T12. In some embodiments, one or more signal delivery devices can be implanted at other vertebral levels, e.g., as disclosed in U.S. Patent Application Publication No. 2013/0066411, which is incorporated herein by reference in its entirety. For example, the one or more signal delivery devices can be implanted using methods and at locations suitable for DBS, PNS, sacral stimulation, and/or other types of stimulation involving implantable leads.


The signal generator 101 can transmit signals (e.g., electrical signals) to the signal delivery elements 110 that up-regulate (e.g., excite) and/or down-regulate (e.g., suppress) target nerves. As used herein, and unless otherwise noted, the terms “modulate,” “modulation,” “stimulate,” and “stimulation” refer generally to signals that have either type of the foregoing effects on the target nerves. Accordingly, a spinal cord “stimulator” can have an inhibitory effect on certain neural populations. The signal generator 101 can include a machine-readable (e.g., computer-readable) or controller-readable medium containing instructions for generating and transmitting suitable therapy signals. The signal generator 101 and/or other elements of the system 100 can include one or more processor(s) 107, memory unit(s) 108, and/or input/output device(s) 112. Accordingly, the process of providing modulation signals, providing guidance information for positioning the signal delivery devices 110, establishing battery charging and/or discharging parameters, and/or executing other associated functions can be performed by computer-executable instructions contained by, on or in computer-readable media located at the pulse generator 101 and/or other system components. Further, the pulse generator 101 and/or other system components may include dedicated hardware, firmware, and/or software for executing computer-executable instructions that, when executed, perform any one or more methods, processes, and/or sub-processes described in the references incorporated herein by reference. The dedicated hardware, firmware, and/or software also serve as “means for” performing the methods, processes, and/or sub-processes described herein. The signal generator 101 can also include multiple portions, elements, and/or subsystems (e.g., for directing signals in accordance with multiple signal delivery parameters), carried in a single housing, as shown in FIG. 1A, or in multiple housings.


The signal generator 101 can also receive and respond to an input signal received from one or more sources. The input signals can direct or influence the manner in which the therapy, charging, and/or process instructions are selected, executed, updated, and/or otherwise performed. The input signals can be received from one or more sensors (e.g., an input device 112 shown schematically in FIG. 1A for purposes of illustration) that are carried by the signal generator 101 and/or distributed outside the signal generator 101 (e.g., at other patient locations) while still communicating with the signal generator 101. The sensors and/or other input devices 112 can provide inputs that depend on or reflect patient state (e.g., patient position, patient posture, and/or patient activity level), and/or inputs that are patient-independent (e.g., time). Still further details are included in U.S. Pat. No. 8,355,797, incorporated herein by reference in its entirety.


In some embodiments, the signal generator 101 and/or signal delivery devices 110 can obtain power to generate the therapy signals from an external power source 103. For example, the external power source 103 can by-pass an implanted signal generator and generate a therapy signal directly at the signal delivery devices 110 (or via signal relay components). The external power source 103 can transmit power to the implanted signal generator 101 and/or directly to the signal delivery devices 110 using electromagnetic induction (e.g., RF signals). For example, the external power source 103 can include an external coil 104 that communicates with a corresponding internal coil (not shown) within the implantable signal generator 101, signal delivery devices 110, and/or a power relay component (not shown). The external power source 103 can be portable for ease of use.


In some embodiments, the signal generator 101 can obtain the power to generate therapy signals from an internal power source, in addition to or in lieu of the external power source 103. For example, the implanted signal generator 101 can include a non-rechargeable battery or a rechargeable battery to provide such power. When the internal power source includes a rechargeable battery, the external power source 103 can be used to recharge the battery. The external power source 103 can in turn be recharged from a suitable power source (e.g., conventional wall power).


During at least some procedures, an external stimulator or trial modulator 105 can be coupled to the signal delivery elements 110 during an initial procedure, prior to implanting the signal generator 101. For example, a practitioner (e.g., a physician and/or a company representative) can use the trial modulator 105 to vary the modulation parameters provided to the signal delivery elements 110 in real time, and select optimal or particularly efficacious parameters. These parameters can include the location from which the electrical signals are emitted, as well as the characteristics of the electrical signals provided to the signal delivery devices 110. In some embodiments, input is collected via the external stimulator or trial modulator and can be used by the clinician to help determine what parameters to vary. In a typical process, the practitioner uses a cable assembly 120 to temporarily connect the trial modulator 105 to the signal delivery device 110. The practitioner can test the efficacy of the signal delivery devices 110 in an initial position. The practitioner can then disconnect the cable assembly 120 (e.g., at a connector 122), reposition the signal delivery devices 110, and reapply the electrical signals. This process can be performed iteratively until the practitioner obtains the desired position for the signal delivery devices 110. Optionally, the practitioner may move the partially implanted signal delivery devices 110 without disconnecting the cable assembly 120. Furthermore, in some embodiments, the iterative process of repositioning the signal delivery devices 110 and/or varying the therapy parameters may not be performed.


The signal generator 101, the lead extension 102, the trial modulator 105 and/or the connector 122 can each include a receiving element 109. Accordingly, the receiving elements 109 can be patient implantable elements, or the receiving elements 109 can be integral with an external patient treatment element, device or component (e.g., the trial modulator 105 and/or the connector 122). The receiving elements 109 can be configured to facilitate a simple coupling and decoupling procedure between the signal delivery devices 110, the lead extension 102, the pulse generator 101, the trial modulator 105 and/or the connector 122. The receiving elements 109 can be at least generally similar in structure and function to those described in U.S. Patent Application Publication No. 2011/0071593, incorporated by reference herein in its entirety.


After the signal delivery elements 110 are implanted, the patient 190 can receive therapy via signals generated by the trial modulator 105, generally for a limited period of time. During this time, the patient wears the cable assembly 120 and the trial modulator 105 outside the body. Assuming the trial therapy is effective or shows the promise of being effective, the practitioner then replaces the trial modulator 105 with the implanted signal generator 101, and programs the signal generator 101 with therapy programs selected based on the experience gained during the trial period. Optionally, the practitioner can also replace the signal delivery elements 110. Once the implantable signal generator 101 has been positioned within the patient 190, the therapy programs provided by the signal generator 101 can still be updated remotely via a wireless physician's programmer (e.g., a physician's laptop, a physician's remote or remote device, etc.) 117 and/or a wireless patient programmer 106 (e.g., a patient's laptop, patient's remote or remote device, etc.). Generally, the patient 190 has control over fewer parameters than does the practitioner. For example, the capability of the patient programmer 106 may be limited to starting and/or stopping the signal generator 101, and/or adjusting the signal amplitude. The patient programmer 106 may be configured to accept pain relief input as well as other variables, such as medication use.


In any of the foregoing embodiments, the parameters in accordance with which the signal generator 101 provides signals can be adjusted during portions of the therapy regimen. For example, the frequency, amplitude, pulse width, and/or signal delivery location can be adjusted in accordance with a pre-set therapy program, patient and/or physician inputs, and/or in a random or pseudorandom manner. Such parameter variations can be used to address a number of potential clinical situations. Certain aspects of the foregoing systems and methods may be simplified or eliminated in particular embodiments of the present disclosure.



FIG. 1B is a cross-sectional illustration of the spinal cord 191 and an adjacent vertebra 195 (based generally on information from Crossman and Neary, “Neuroanatomy,” 1995 (published by Churchill Livingstone)), along with multiple leads 111 (shown as leads 111a-111e) implanted at representative locations. For purposes of illustration, multiple leads 111 are shown in FIG. 1B implanted in a single patient. In addition, for purposes of illustration, the leads 111 are shown as elongated leads however, leads 111 can be paddle leads. In actual use, any given patient will likely receive fewer than all the leads 111 shown in FIG. 1B.


The spinal cord 191 is situated within a vertebral foramen 188, between a ventrally located ventral body 196 and a dorsally located transverse process 198 and spinous process 197. Arrows V and D identify the ventral and dorsal directions, respectively. The spinal cord 191 itself is located within the dura mater 199, which also surrounds portions of the nerves exiting the spinal cord 191, including the ventral roots 192, dorsal roots 193 and dorsal root ganglia 194. The dorsal roots 193 enter the spinal cord 191 at the dorsal root entry zone 187, and communicate with dorsal horn neurons located at the dorsal horn 186. In some embodiments, the first and second leads 111a, 111b are positioned just off the spinal cord midline 189 (e.g., about 1 mm. offset) in opposing lateral directions so that the two leads 111a, 111b are spaced apart from each other by about 2 mm, as discussed above. In some embodiments, a lead or pairs of leads can be positioned at other locations, e.g., toward the outer edge of the dorsal root entry zone 187 as shown by a third lead 111c, or at the dorsal root ganglia 194, as shown by a fourth lead 111d, or approximately at the spinal cord midline 189, as shown by a fifth lead 111e.


In any of the foregoing embodiments, it is important that the signal delivery device 110 and in particular, the therapy or electrical contacts of the device, be placed at a target location that is expected (e.g., by a practitioner) to produce efficacious results in the patient when the device 110 is activated. The following sections describe techniques and systems for simplifying the process of placing contacts via one or more leads 111 which to deliver neural modulation signals to the patient.


2.0 Representative Embodiments

Systems of the type described above with reference to FIGS. 1A-1B can be used to treat patient pain without generating paresthesia, via therapy signals delivered at a frequency between 1.5 kHz and 100 kHz, or between 1.2 kHz and 100 kHz. In addition, systems of the type described above with reference to FIGS. 1A-1B can be used with various therapies using low frequency (LF) that generate paresthesia. The following discussion with reference to FIGS. 2A-6D describes various embodiments of leads having openings disposed within a sidewall of the lead and a lumen extending through a length of the lead to a distal and/or proximal portion of the lead, and are configured to receive a stylet. Compared to leads configured to receive a stylet at a proximal opening, the leads described below with reference to FIGS. 2A-6D can have improved steerability to facilitate more efficient and accurate positioning within a patient, and/or with respect to a pulse generator or other hardware to which the lead may be connected. In some embodiments, the leads can be implantable leads, such as elongated leads or paddle leads. Such leads can be used to deliver any of a variety of suitable electrical signals in addition to or in lieu of signals having a frequency between 1.2 kHz and 100 kHz, such as electrical signals having a frequency between about 5 Hz and 100 Hz, between about 25 Hz and about 75 Hz, and between about 50 Hz and about 100 Hz.



FIG. 2A illustrates a side view of a lead 111 having a sidewall 118, an internal lumen 115 positioned inwardly from the sidewall 118, and one or more openings 117 (e.g., ports) disposed within the sidewall 118 to provide a passage to the lumen 115. Leads 111 configured in accordance with the present technology are generally elongated (e.g., having a greater longitudinal dimension than a lateral dimension), and can include paddle leads, as illustrated in FIG. 5. As shown in FIG. 2A, the lead 111 includes a lead body having a proximal portion 111f, a distal portion 111g, and an intermediate portion 111h disposed between the proximal portion 111f and the distal portion 111g. The lead 111 further includes a distal end 111i and a proximal end 111j. The lead lumen 115 can be configured to removably receive at least a portion of a stylet 130 (e.g., a stylet shaft 131) that is sized and shaped to be inserted into the lead lumen 115 through a first opening 117a (e.g., a stylet entry point). Once delivered through the first opening 117a, the stylet shaft 131 is temporarily coupled to the lead 111 to support the lead 111 as it is inserted into the patient at the desired location, and, more specifically, into the patient's epidural space in accordance with some embodiments of the present technology. In other embodiments, the lead can be inserted into the patient's brain or peripheral tissue. The stylet 130 can include a handle 133 that can be fixedly or removably attached to the stylet shaft 131. The handle 133 and the stylet shaft 131 can be made of any number of suitable biocompatible materials. In some embodiments, for example, the handle 133 comprises a thermoplastic such as acrylonitrile butadiene styrene (ABS).


As illustrated in FIG. 2A, when the stylet 130 is inserted into the lead lumen 115, a distal region 130a of the stylet 130 can extend distally through the lumen 115 until a tip 135 of the stylet is positioned proximate to the distal end 111i of the lead 111. The stylet tip 135 can be an atraumatic tip and is thereby restricted/prevented from extending through the distal end 111i of the lead 111. As used herein, and unless otherwise noted, “atraumatic” means causes minimal, if any, injury to a patient's tissue. Alternatively, or in addition to the atraumatic stylet tip 135, when the practitioner moves the stylet 130 through the lead lumen 115 to the distal end 111i, the tip 135 can eventually abut a stylet stop (not shown) located at a terminus of the lead lumen 115, and is therefore unlikely to puncture through the distal end 111i.


In some embodiments, the lead 111 can include more than one opening 117 operably connected to more than one lead lumen 115, each of which can extend distally from each of the openings 117. For example, the lead 111 can include the first opening 117a coupled to a first lead lumen, another opening coupled to a second lead lumen, yet another opening coupled to a third lead lumen, and so on. In some embodiments, each of the openings 117 and lead lumens 115 can be configured to receive the stylet shaft 131 or other elongated shaft configured to support, position, or otherwise facilitate delivery or other handling of the lead 111. In some embodiments, the lead 111 can include more than one opening 117 coupled to a single lead lumen 115, such as two openings (e.g., shown by reference numbers 117a and 117b in FIG. 2A) coupled to the same lead lumen 115, or more than one opening coupled to a first lead lumen and more than one opening coupled to a second lead lumen. Accordingly, the practitioner can pick the opening 117 corresponding to the desired stylet-supported length of the lead 111 suitable for a given patient. When configured with more than one opening 117 and, optionally, more than one lead lumen 115, the lead 111 can be coupled to a first elongated stylet shaft in a first lead lumen and a second elongated stylet shaft in a second lead lumen, etc. Alternatively, the stylet shaft 131 can be inserted into the first opening, removed, and inserted into the second opening that is positioned proximally or distally relative to the first opening along the sidewall 118 of the lead 111. In still further embodiments, the lead can include a third opening 117c that provides stylet access from the intermediate portion 111h to the proximal portion 111f, in addition to, or in lieu of, the first opening 117a that provides access from the intermediate portion 111h to the distal portion 111g. As will be described further with reference to FIGS. 6A-6D, the third lead opening 117c can be used to support the proximal portion of lead 111 as it is inserted into the pulse generator 105 and/or other hardware elements, e.g., the lead extension 102 and/or cable assembly 120 described above with reference to FIG. 1A.


The lead 111 can further include a membrane that is configured to be penetrated by the stylet shaft 131 and seal at least a portion of a corresponding opening 117 prior to or after engaging the stylet shaft 131. Representative membranes 113 can be plugs or valves (e.g., one-way valves) or continuous structures that can be punctured, torn, or otherwise opened to allow the stylet shaft 131 to enter the lead lumen 115 through the opening 117. In some embodiments, the membrane 113 is a self-sealing septum valve that permits the stylet shaft 131 to pass through, and upon removal of the stylet shaft 131, re-seals to close the lead lumen 115. For example, FIG. 2B illustrates a portion of a representative lead 111 having a lead lumen 115, internal wires 119 that connect to contacts or electrodes (not visible in FIG. 2B), and an opening 117 to provide stylet access into the lead lumen 115. A membrane 113 is positioned over or in the opening 117, and includes a slit 114 that is sized to allow a stylet to be inserted into, and withdrawn from, the opening 117, with the membrane 113 being sufficiently resilient to re-seal the slit 114 when the stylet is withdrawn. In some embodiments, the membrane 113 can be formed from a rigid, semi-rigid, or flexible material to facilitate such sealing, thereby preventing fluid and/or air from entering the lumen 115. In addition, the geometry of the membranes 113 may correspond to that of the openings 117. For example, membranes 113 may have similar cross-sectional geometry as that of the openings 117, to provide proper sealing. The size, diameter, etc. of the membranes 113 may exceed that of the openings 117 by a margin sufficient to facilitate sealing the openings 117.


Referring again to FIG. 2A, in some embodiments, the lead 111 can be elongated along a major or lead axis, such as a longitudinal axis LA. In general, the term “elongated” refers to a physical characteristic of a structure having a length greater than its width. The lead 111 can have an overall lead length L between the distal end 111i and the proximal end 111j that is longer than that of typical leads. For example, the lead length L can be sufficient to position one or more of the signal delivery elements 110 at one or more vertebral locations (including associated neural populations) described herein. For example, the contacts C1-C8 may be positioned at vertebral levels T9-T12 to treat low back pain. Representative lead lengths L are from about 30 cm to about 150 cm, and in some embodiments, from about 40 cm to about 50 cm. As used herein, “about” means within ±10% of the stated value, unless otherwise noted. To accommodate patients having different physical characteristics, leads of the present disclosure can have a lead length L of about 40 cm, about 45 cm, about 50 cm, about 55 cm, about 60 cm, about 65 cm, about 70 cm, about 75 cm, about 80 cm, about 85 cm, about 90 cm, about 95 cm, or about 100 cm.


As described above, the lead lumen 115 extends between the first opening 117a and the distal portion 111g of the lead 111. In some embodiments, the lead lumen 115 extends all the way to (but not through) the distal end 111i rather than only partially within the distal portion 111g. To increase the steerability of the lead 111 compared to other leads, the first opening 117a can be positioned within the sidewall 118 of the intermediate portion 111h of the lead 111. A steerable lead length SL is defined by a longitudinal length of the lead lumen 115 that is accessible to a stylet via an opening. The steerable length SL is typically less than the overall length L of the lead. In this way, rather than steering the entire lead length L of the lead 111 through a lead lumen 115 extending the entire lead length, a practitioner inserts the stylet shaft 131 and actively steers just the steerable lead length SL. The rest of the lead 111 follows. This can increase the practitioner's efficiency and accuracy when positioning the lead 111 within the patient at a treatment site, compared to leads having lumens extending generally into proximal portions of the leads and coupled to proximal openings configured to receive stylets.


Leads in accordance with some embodiments of the present technology can have a steerable length of about 20 cm, about 25 cm, about 30 cm, about 35 cm, about 40 cm, about 45 cm, or about 50 cm, depending on the length of the lead. For example, a representative lead can have a length of 50 cm and a steerable length of 30 cm. Other combinations of lengths and steerable lengths can be selected based on one or more of the patient's physical characteristics. In addition, the lead 111 can include one or more markers (not shown) with each marker indicating a length interval. For example, leads can include markers positioned longitudinally along the steerable length SL and/or lead length L at intervals of 10 cm, such as a lead 111 having an 80 cm length with seven markers spaced 10 cm apart. Practitioners can refer to these markers as the lead 111 is being delivered to, and positioned within, the patient to provide feedback to the practitioner as to what length of the lead 111 has been delivered to the patient.


In some embodiments, the lead 111 can be formed of a single biocompatible material. In some embodiments, the lead 111 can be formed of more than one biocompatible material. For example, more than one biocompatible material can be used over the entire length L of the lead 111, such as a first material forming a first layer, a second material forming a second layer, and so on. In addition to or in lieu of this arrangement, the distal portion 111g of the lead 111 can be formed of a first material, the intermediate portion 111h can be formed of a second material, and the proximal portion 111g can be formed of a third material. Each of these portions can further include layers formed of the same material or a different material. In some embodiments, the distal portion 111g of the lead 111 can be formed of a similar or the same material(s) as the intermediate portion 111h of the lead 111. The material(s) can be selected to form certain portions of the lead 111, and/or to form certain layers of the lead 111, and/or to prevent the stylet 130 from puncturing a portion of the lead 111 as the distal region 130a of the stylet shaft 131 is being delivered to and through the opening 117.


Regardless of the material(s) forming the lead 111, the materials can have different stiffnesses. As such, leads configured in accordance with the present disclosure can be formed of any number of suitable biocompatible materials (e.g., polyurethane and/or silicone, with or without heat treatment and/or other strengthening/reinforcement agents) having a plurality of different stiffnesses. Stiffness, as used herein, refers to a resistance of a material (of the lead) to bending away from the longitudinal axis L of the lead 111. In this way, one or more material(s) can be selected to form a lead 111 having one or more desired stiffnesses along a length L of the lead 111. For example, the distal portion 111g of the lead 111 and the intermediate portion 111h of the lead 111 together can have a first stiffness and the proximal portion 111g of the lead 111 can have a second, different (e.g., greater) stiffness. In some embodiments, the distal portion 111g of the lead 111 can have a third stiffness, the intermediate portion 111h of the lead 111 can have a fourth stiffness, and the proximal portion 111g of the lead 111 can have a fifth stiffness. Similar to the first stiffness and the second stiffness, the third, fourth, and fifth stiffnesses can be generally similar or different. For example, the fifth stiffness can be stiffer than the fourth stiffness which can be stiffer than the third stiffness.


The stiffnesses of the portions of the lead 111 can be generally similar or different. For example, the second stiffness of the proximal portion 111g of the lead 111 can be greater than the first stiffness of the distal portion 111g of the lead 111 and the intermediate portion 111h of the lead 111. In this configuration, the distal portion 111g of the lead 111 and the intermediate portion 111h of the lead 111 comprise the steerable length SL, and the proximal portion 111f comprises an external length EL of the lead 111. As such, the stiffness of the external length EL is greater than the stiffness of the steerable lead length SL. Moreover, when configured to have the first stiffness and the second stiffness, a transition point or region between the first stiffness and the second stiffness can be formed and is often positioned at or near the first opening 117a.


The lead 111 terminates at the distal end 111i which can be made of the same material as the rest of the lead 111, the same as a material used to form a portion of the lead 111, or can be made of a separate material or component. In some embodiments, the distal end 111i can include a radiopaque portion 123 made of, for example, titanium dioxide or barium sulfate, to aid in positioning the lead 111 via fluoroscopy or another suitable visualization technique.


In some embodiments, the stylet shaft 131, or a portion of the stylet shaft, has a stiffness greater than a stiffness of the lead 111 in which it is inserted. In some embodiments, at least a portion of the stylet shaft 131 can be coated with a layer of polytetrafluoroethylene (PTFE) or another suitable fluoropolymer.


The lead 111 can have a plurality of signal delivery elements 110 (e.g., contacts C1-C8) carried by the distal portion 111h of the lead 111 and can be positioned to deliver modulation signals in accordance with some embodiments of the disclosure. The signal delivery elements 110 are accordingly positioned to contact the patient's tissue when implanted. The contacts C can be ring-shaped and/or can have other shapes. The lead 111 includes internal wires or conductors (described further below with reference to FIGS. 3A-3D) that extend between the proximal end 111j of contacts C at or near the distal region 111g of the lead 111. The contacts C can be made of any suitable biocompatible metal such as titanium, a noble metal such as platinum or iridium, or alloys thereof. In some embodiments, the contacts C can be coated with materials to improve contact performance or increase the surface area of the contacts C. These materials can include, for example, platinum black, titanium nitride, iridium oxide, or other materials having generally similar material properties. After implantation, the connection contacts C are connected to the external programmer 105 or to the implanted pulse generator 101 discussed above with reference to FIG. 1A.


The lead 111 can be introduced into the patient via a needle, catheter, or the like. In use, the practitioner inserts the stylet shaft 131 into the lead lumen 115, which generally straightens the distal portion 111g of the lead 111 and the intermediate portion 111h of the lead for implantation. Together, the distal region 130a of the stylet 130 and the distal portion 111g of the lead 111 form a distal zone which can be generally straight, optionally with a curved tip (not shown) to aid in steering the lead. Prior to implantation, the shaft 131 of the stylet 130 or other delivery device is slideably and releasably inserted (via the handle 133) into an axially-extending opening (lead lumen 115) in the lead 111 via the opening 117. Once inserted, the shaft 131 extends distally through the lumen 115 along the steerable length SL of the lead 111. During implantation, the lead 111 is positioned in a catheter (not shown) which is inserted into the patient's body. The lead 111 can then be deployed from the catheter using the stylet 130, which supports the lead 111 as the stylet 130 and the lead 111 are moved together until the distal portion 111g and the associated contacts C1-C8 are at the desired location (e.g., treatment site) in the patient. The shaft 131 can generally be flexible, but more rigid than the lead 111, to allow the practitioner to insert the lead 111 and control its position. The lead 111 can be anchored in place once the distal portion 111g is positioned at or near the treatment site. As discussed later, with reference to FIG. 4, suitable anchors can be attached to adjacent ligaments, bone, and/or other structures.


After positioning the lead 111, the stylet shaft 131 can be readily and freely removed from the lead lumen 115 by withdrawing the distal end 130a of the stylet shaft 131 away from the spinal cord modulation site and extracting the stylet shaft 131 from the lead lumen 115. In some embodiments, at least one of an inner surface of the lead lumen 115 and an outer surface of the stylet shaft 131 can include a material positioned to facilitate relative sliding and free separation between the surfaces. For example, a PTFE liner or the coating can be placed on an inner surface of the lead lumen 115, in addition to or in lieu of placing it on the stylet shaft 131. Upon removal, at least the distal portion 111g of the lead 111 remains generally straight at the desired treatment location. In some embodiments, a portion of the intermediate portion 111h can also remain generally straight.



FIG. 3A is a cross-sectional illustration of a representative lead 111 having a circular cross-sectional shape, taken generally along line 3A-3A of FIG. 2A. One or more internal wires 119 can electrically connect the contacts C1-C8 (FIG. 2A) to other features of the systems described herein with reference to FIG. 1A, such as the external programmer 105. In the illustrated embodiment, the internal wires 119 are housed in corresponding wire lumens that extend longitudinally along the length of the lead 111 and are positioned adjacent to the sidewall 118. In general, the lead lumen 115 is positioned in a generally central portion of the lead 111 with respect to the longitudinal axis LA. In some embodiments, the lead 111 can also have an elliptical cross-section as illustrated in FIG. 3C, rather than the generally circular cross-section illustrated in FIG. 3A. In addition, as illustrated in FIG. 3B and FIG. 3D, the lead lumen 115 can be positioned adjacent to the sidewall 118 along with the internal wires 119 rather than in the generally central portion of the lead 111 shown in FIGS. 3A and 3C.


Referring next to FIG. 4, the lead 111 can further include a lead anchor 140, which releasably carries the lead 111 and can anchor the lead 111 in a position relative to the patient's tissue. For example, when the distal portion 111g is positioned at the treatment site, the practitioner can secure the intermediate portion 111h relative to the patient with the lead anchor 140 and can partially or completely remove the stylet 130 from the lead lumen 115 through the sidewall opening 117. Lead anchors 140 useful with leads of the present technology can have an anchor stiffness greater than any lead stiffness and can prevent the stylet from extending outwardly from the lead body. For example, when the lead anchor 140 is positioned around a portion of the sidewall 118 carrying the opening 117, the anchor 140 can provide added stiffness to the portion of the sidewall 118 thereby preventing the portion of the sidewall 118 from being penetrated and/or perforated by the stylet tip 130a.


The lead anchor 140 can include a longitudinally-extending anchor body 143 having a longitudinally extending aperture 145 that receives the lead 111. The anchor body 143 includes a sleeve 144 in which the longitudinally extending aperture 145 is positioned. The aperture 145 is sized and configured to receive the lead 111 therethrough. A retainer 146 is disposed around the sleeve 144 and is operable to compress or constrict at least a portion of the sleeve 144 against the lead 111 extending through the sleeve 144. The lead 111 is accordingly retained in position relative to the anchor 140 by friction developed between the sleeve 144 and lead 111 due to the compression force exerted by the retainer 146. In general, the circumferential extent of the retainer 146 is sufficient to capture and/or compress the lead 111 in a generally uniform manner. The sleeve 144 and the retainer 146 can be formed from any biocompatible material suitable to exert sufficient compression force to retain the lead 111 in position within longitudinally extending aperture 145, e.g., as disclosed in U.S. Patent Application Publication No. 2015/0005859, which is incorporated herein by reference in its entirety.


The lead anchor 140 can further comprise one or more anchor tabs 147 extend laterally from the anchor body 143 e.g., on opposite sides. Each anchor tab 147 can include an aperture 149 or other feature to facilitate attaching the lead anchor 140 to a patient's tissue.


In some embodiments, the lead anchor 140 can be configured to mate with the lead using any number of suitable lead anchor 140 mating features (not shown), such as through an opening, a groove, a slit, a channel, or the like, to receive the lead body. In some embodiments, the lead anchor 140 can be used to help seal the opening 117 into the lead lumen 115. Accordingly, the lead 111 can have pre-set anchor locations near (or coincident with) the opening 117.


In a representative embodiment illustrated in FIG. 5, the lead is a paddle lead 180 and includes a paddle body 120 elongated along a longitudinal axis 141. The paddle body 120 has a length L along the longitudinal axis 141, a width W transverse to the longitudinal axis 141, and a thickness T transverse to the width W. In general, the paddle body 120 has a flattened configuration, with the thickness T less than the width W and the length L. The paddle body 120 can have a first or upper surface 122 and a second or lower surface 123. The paddle body 120 carries one or more contacts C that are accessible from the lower surface 121. Accordingly, when the paddle body 120 is implanted, the contacts C at the lower surface 133 are positioned to direct electrical signals toward the target location, e.g., the spinal cord.


Electrical current is directed to the paddle body 120 via one or more lead tails 138, each of which carries one or more conductors 139 (shown schematically in FIG. 5). For example, the paddle body 120 can carry 16 contacts C, which are supplied with electrical current by a corresponding set of sixteen conductors 139, eight of which are housed in one lead tail 138, and the remaining eight of which are housed in the other lead tail 138. The lead tails 138 connect to the paddle body 120 at corresponding lead legs 125. The lead legs 125 can be separated by a gap 126 having a longitudinal dimension G generally aligned with the longitudinal axis 141. Additional features of the paddle lead 180 are disclosed in U.S. Patent Application Publication No. 2018/0256892, which was previously incorporated herein by reference in its entirety.


Similar to the lead 111 of FIG. 2A, the lead tails 138 illustrated in FIG. 5 can each include a lead tail sidewall 118a, an internal lead tail lumen 115a positioned inwardly from the lead tail sidewall 118a, and a lead tail opening 117a disposed within the lead tail sidewall 118a to provide a passage to the lead tail lumen 115a. The lead tails 138 each include a lead tail body 138a having a lead tail proximal portion 138b, a lead tail distal portion 138c, and a lead tail intermediate portion 138d disposed between the lead tail proximal portion 138b and the lead tail distal portion 138c. The lead tails 138 further include a lead tail distal end 138e and a lead tail proximal end 138f. The lead tail lumen 115a can be configured to removably receive at least a portion of a stylet 130 (e.g., a stylet shaft 131) that is sized and shaped to be inserted into the lead tail lumen 115a through the lead tail opening 117a. When the stylet 130 is inserted into the lead tail lumen 115a, a distal region 130a of the stylet 130 can extend distally through the lead tail lumen 115a until a tip 135 of the stylet is positioned proximate to the lead tail distal end 138e of the lead tail 138. Unless stated otherwise, the lead tails 138 of FIG. 5 behave similarly to lead 111 described above and illustrated in FIG. 2A. For example, when the practitioner inserts the stylet shaft 131 into the lead tail lumen 115a, the inserted stylet shaft 131 generally straightens the lead tail distal portion 138c and the lead tail intermediate portion 138d for implantation. In another embodiment, the paddle lead 180 can be delivered into the patient using one stylet 130. The stylet 130 can be introduced into the paddle body 120 itself, such as into a paddle lumen (not shown) through a paddle opening 137 operatively connected to the paddle lumen (not shown). In this embodiment, the paddle body 120 can be steered in a similar manner as described above with respect to the lead tails 138 and the leads 111.


As described above, the distal portion 138c corresponds to the distal portion of the lead tail 138. Accordingly, the lead tail lumen 115a extends through the distal portion 138c to the end of the distal portion 138c. Alternatively, the lead tail 138 and the paddle body 120 can be considered together, with the paddle body 120 forming the distal portion of the overall lead 180. Accordingly, the lead tail lumen 115a extends to but not through the distal portion. To provide greater control over the paddle lead 180, the lead lumen can extend to and through the distal portion (e.g., paddle body 120) to the end of the paddle body 120, as indicated by reference numeral 115b. Accordingly, in some embodiments, the lead lumen extends to the distal portion of the lead, or into the distal portion of the lead, or entirely through the distal portion of the lead to the end of the distal portion (but not so far as to puncture through the distal end of the lead).


With any of the foregoing leads and associated systems, it is important for the practitioner to accurately position the lead in order to provide effective therapy. With varying patient anatomies and tight spaces in which to navigate, practitioners often must position and re-position the lead during implantation in order to accurately place the lead at a target treatment site. Compared to shorter leads, leads having longer lengths are more difficult for practitioners to steer during positioning, which can increase the duration of an implantation procedure or reduce accuracy of lead placement. For example, the greater length of the lead adds uncertainty about the correlation between a given movement or action by the practitioner at the proximal end of the lead, and the resulting movement or action of the lead at the distal end. This applies to linear motions (lateral and/or axial) and rotational motions. More specifically, the stylet may have a curved tip. By rotating the stylet, the practitioner can change the direction in which the curved tip points, and therefore, the direction in which the lead travels. For long leads, the practitioner's rotation of the stylet at the proximal end may not correspond to a similar rotation at the distal end because the stylet is at least somewhat torsionally flexible—and over greater lead lengths, the torsional flexibility produces a greater disparity between the amount of stylet rotation at the proximal end and the corresponding rotation of the distal end of the stylet. In still another example, the stylet may buckle when an axial force is applied to it over a great distance. Accordingly, the process of placing the lead can be difficult. As a result, there exists a need for a lead which provides for precise navigation regardless of the lead length. As discussed herein, embodiments of the present technology include leads having various lead lengths L yet can be steered by a practitioner as though each of the leads have generally similar lead lengths L, e.g., because the different leads have steerable lengths SL that are similar or the same. Accordingly, a practitioner who becomes proficient at steering a lead with a given total length and steerable length can apply that proficiency to a lead having a different total length, but the same steerable length.


Several of the embodiments described above were described in the context of sidewall openings that facilitate improved handling of the distal end of the lead. In addition to, or in lieu of, improving handling of the distal portion, sidewall openings can improve the practitioner's ability to handle the proximal portion of the lead. Representative embodiments of such sidewall openings are described further below with reference to FIGS. 6A-6D.



FIG. 6A is a partially schematic illustration of a representative signal generator 101 and the proximal portion 111f of a corresponding lead 111. The signal generator 101 includes a body or can 195 in which the processor, battery, and/or other electronic components are typically housed. The signal generator 101 can also include a header 196 that is configured to connect the internal electronics to the lead 111. In a representative embodiment shown in FIG. 6A, the header 196 includes two receiving elements 109, each configured to receive a corresponding lead 111. Each of the receiving elements 109 includes header contacts E positioned to align with, and electrically contact, corresponding proximal contacts P carried by the lead 111. The proximal contacts P are electrically connected to the distal contacts C (shown in FIG. 2A) with corresponding conductors 119 (shown in FIGS. 3A-3D). The intermediate portion 111h of the lead 111 can include a third opening 117c that provides access to the lumen 115 for a stylet 130. The stylet 130 can be inserted into the third opening 117c until the end of the stylet 130 is positioned at or close to the proximal end 111j of the lead 111. In this manner, the practitioner can temporarily support the proximal portion 111f of the lead 111 as the lead is being inserted into the corresponding receiving element 109 of the signal generator 101. The additional stiffness provided by the stylet 130 can make it easier for the practitioner to insert the lead 111 into the receiving element 109. After the lead 111 has been successfully inserted into the receiving element 109, the practitioner withdraws the stylet 130.


One feature of the foregoing arrangement described above with reference to FIG. 6A is that the lead 111 is only temporarily supported by the stylet 130 during the time it takes to successfully insert the lead 111 into the signal generator 101. This approach avoids the need to insert epoxy or another stiffening agent into the stylet lumen 115. In addition to reducing the number of manufacturing steps required to produce the lead, eliminating the need to permanently stiffen the proximal portion 111f of the lead 111 reduces the likelihood for a stiffened portion of the lead to project outwardly from the signal generator 101, which can be uncomfortable for the patient. Instead, after the stylet 130 has been removed, the entire proximal portion 111f of the lead that extends out from the signal generator 101 is relatively flexible, and is therefore less likely to create discomfort for the patient.


The proximal end 111j of the lead 111 can have a variety of different configurations. For example, referring first to FIG. 6B, the proximal end 111j can be closed so as to provide full support for the proximal tip 135a of the stylet shaft 131. In another embodiment, shown schematically in FIGS. 6C and 6D, the proximal end 111j of the lead 111 can include an end opening 116. The end opening 116 is small enough that the stylet shaft 131 will not extend through it. The end opening 116 is large enough to accommodate a smaller, second stylet 132, as shown in FIG. 6D. The second stylet 132 can be inserted from the proximal end toward the distal end, if needed for steering during lead insertion, and/or for making subsequent adjustments to the position of the lead, and/or for extracting the lead.


From the foregoing, it will be appreciated that some embodiments of the presently disclosed technology have been described herein for purposes of illustration, but various modifications may be made without deviating from the disclosed technology. For example, the leads and lead lumens can have lengths and/or shapes that differ from those specifically described above. In addition, the leads can include one or more openings positioned at a number of different locations in the distal portion and/or the intermediate portion of the leads. For leads having stylet access to both the distal and proximal ends of the lead, that access can be provided via a single lumen that extends from the proximal end to the distal end, or two lumens, one extending from the intermediate portion of the proximal end, and one extending from the intermediate portion to the distal end.


Certain aspects of the technology described in the context of some embodiments may be combined or eliminated in some embodiments. For example, in some embodiments, the lead and stylet can comprise a device, a system, or portions thereof. Furthermore, leads can be coupled to the stylets prior to inserting the lead into the delivery device (e.g., catheter) and can be provided to a practitioner as a set including the lead and the stylet. Additionally, the stylets disclosed herein can be used with leads having shapes or designs other than those specifically described above.


While advantages associated with some embodiments of the disclosed technology have been described in the context of those embodiments, not all embodiments need necessarily exhibit such advantages to fall within the scope of the present technology. To the extent that any of the foregoing patents, published applications, and/or other materials incorporated herein by reference conflict with the present disclosure, the present disclosure controls.


The following examples are provided to further illustrate embodiments of the present technology and are not to be interpreted as limiting the scope of the present technology. To the extent that certain embodiments or features thereof are mentioned, it is merely for purposes of illustration and, unless otherwise specified, is not intended to limit the present technology. One skilled in the art may develop equivalent means without the exercise of inventive capacity and without departing from the scope of the present technology. It will be understood that many variations can be made in the procedures herein described while still remaining within the bounds of the present technology. Such variations are intended to be included within the scope of the presently disclosed technology. As such, embodiments of the presently disclosed technology are described in the following representative examples.


1. A patient therapy device, comprising:

    • a patient-implantable lead having a proximal portion, an intermediate portion and a distal portion, at least one electrical contact disposed at at least one of the distal portion or the proximal portion, and a lumen inside of the lead, wherein the lumen extends from at least one of a distal end or a proximal end of the lead at least to an opening disposed within a sidewall of the intermediate portion; and
    • a stylet having a shaft with a proximal region and a distal region, wherein the distal region of the stylet is sized and shaped to be removably inserted into the lumen through the opening.


2. The patient therapy device of clause 1, wherein the distal region and the distal portion together comprise a distal zone of the device.


3. The patient therapy device of clause 2, wherein the distal zone of the device is generally straight.


4. The patient therapy device of any of the foregoing clauses, wherein the distal portion of the lead is generally straight in a deployed configuration.


5. The patient therapy device of any of the foregoing clauses, wherein the lead has a lead length measured from the proximal end of the lead to the distal end of the lead.


6. The patient therapy device of clause 5, wherein the lead length is selected from the group consisting of about 50 centimeters (cm), about 55 cm, about 60 cm, about 65 cm, about 70 cm, about 75 cm, about 80 cm, about 85 cm, about 90 cm, about 95 cm, and about 100 cm.


7. The patient therapy device of clause 6, wherein the lead has a steerable length extending from the opening to the distal end of the lead.


8. The patient therapy device of clause 7, wherein the steerable length is selected from the group consisting of about 10 cm, about 15 cm, about 20 cm, about 25 cm, about 30 cm, about 35 cm, about 40 cm, about 45 cm, and about 50 cm.


9. The patient therapy device of clause 8, wherein the lead has a lead length selected from the group consisting of about 50 cm, about 60 cm, and about 70 cm, and the lead has a steerable length of about 30 cm.


10. The patient therapy device of clause 1, wherein the lead has a steerable length extending from the opening to the proximal end of the lead.


11. The patient therapy device of clause 10, wherein the steerable length from about 1 cm to about 10 cm.


12. The patient therapy device of clause 11, wherein the steerable length is about 2.5 cm.


13. The patient therapy device of any of the foregoing clauses, wherein the lead is a first lead having a first lead length and a first steerable length extending from the opening of the first lead to the distal end of the first lead and wherein the therapy device further comprises a second lead having a second lead length different than the first lead length, and a second steerable lead length at least approximately the same as the first steerable lead length.


14. The patient therapy device of clause 13, further comprising a third lead having a third lead length different than the first and second lead lengths, and a third steerable lead length at least approximately the same as the first steerable lead length.


15. The patient therapy device of any of the foregoing clauses, wherein the lumen extends longitudinally along a longitudinal axis of the lead between the opening and the at least one of the distal end or the proximal end, and is positioned centrally in the lead, when viewed in a cross-section normal to the longitudinal axis of the lead.


16. The patient therapy device of any of the foregoing clauses, wherein the lumen extends longitudinally along a longitudinal axis of the lead between the opening and the at least one of the distal end or the proximal end, and is positioned off-center in the lead, when viewed in a cross-section normal to the longitudinal axis of the lead.


17. The patient therapy device of any of the foregoing clauses, wherein the intermediate portion of the lead and the at least one of the distal portion or the proximal portion of the lead have a generally circular cross-sectional shape.


18. The patient therapy device of any of the foregoing clauses, wherein the intermediate portion of the lead and the at least one of the distal portion or the proximal portion of the lead have an elliptical cross-sectional shape.


19. The patient therapy device of any of the foregoing clauses, wherein the distal portion and the intermediate portion together have a first stiffness and the proximal portion has a second stiffness greater than the first stiffness.


20. The patient therapy device of any of the foregoing clauses, further comprising a lead anchor coupleable to the lead.


21. The patient therapy device of clause 20, wherein the lead anchor further comprises:

    • a longitudinally extending sleeve having an aperture sized and positioned to receive the lead; and
    • a retainer disposed around the sleeve and operable to compress at least a portion of the sleeve against the lead.


22. The patient therapy device of clause 21, wherein the lead anchor further comprises at least one anchor tab positioned to facilitate attaching the lead anchor to a patient.


23. The patient therapy device of clause 21, wherein the anchor is positioned to engage the intermediate portion of the lead comprising the opening.


24. The patient therapy device of clause 20, wherein the anchor has a stiffness greater than a stiffness of the proximal portion of the lead.


25. The patient therapy device of any of the foregoing clauses, wherein the opening is a first opening and wherein the lead has a second opening disposed in the sidewall of the intermediate portion, the first opening being positioned between the second opening and the distal portion.


26. A spinal cord modulation lead for positioning within a patient and delivering electrical modulation signals to the patient at a treatment site, the lead comprising:

    • at least one electrical contact; and
    • a lead body having;
      • a proximal portion,
      • a distal portion, wherein the at least one electrical contact is disposed at the distal portion,
      • an intermediate portion disposed between the proximal portion and the distal portion,
      • a distal end, wherein the distal end is atraumatic
      • a sidewall extending longitudinally along a longitudinal axis of the lead body,
      • the sidewall having an opening at the intermediate portion, and
      • a lumen positioned interiorly from the sidewall and extending longitudinally between the distal end and the opening.


27. The lead of clause 26, wherein the opening is sized and shaped to receive a stylet removably insertable into the lumen through the opening.


28. The lead of clause 27, further comprising a membrane penetrable by the stylet and positioned over or within the opening.


29. The lead of clause 28, wherein the membrane includes a plug or a valve.


30. The lead of clause 29, wherein the valve includes a one-way valve.


31. The lead of clause 30, wherein the one-way valve includes a septum valve.


32. The lead of clause 26, wherein the distal portion is generally straight when positioned at the treatment site.


33. The lead of any of clauses 26-32, wherein the lead has a lead length extending between a proximal end of the lead and the distal end.


34. The lead of clause 33, wherein the lead length is selected from the group consisting of about 50 centimeters (cm), about 55 cm, about 60 cm, about 65 cm, about 70 cm, about 75 cm, about 80 cm, about 85 cm, about 90 cm, about 95 cm, and about 100 cm.


35. The lead of clause 26, wherein the lead has a steerable length extending between the opening and the distal end of the lead.


36. The lead of clause 35, wherein the steerable length is selected from the group consisting of about 10 cm, about 15 cm, about 20 cm, about 25 cm, about 30 cm, about 35 cm, about 40 cm, about 45 cm, and about 50 cm.


37. The lead of clause 26, wherein the lead has a lead length selected from the group consisting of about 50 cm, about 60 cm, and about 70 cm, and the lead has a steerable length of about 30 cm.


38. The lead of clause 26, wherein the distal portion and the intermediate portion together have a first stiffness and the proximal portion has a second stiffness greater than the first stiffness.


39. The lead of any of clauses 26-38, wherein the at least one contact is a first electrical contact and the opening is a first opening, and wherein the lead further comprises a second electrical contact at the proximal portion, and wherein the lead has a second opening in the sidewall, the second opening being between the first opening and a proximal end of the lead, with the lumen extending proximally from the second opening to the proximal end of the lead.


40. A method for treating a patient, comprising:

    • inserting a stylet into an opening within a sidewall of the lead, wherein the opening is located in an intermediate portion of the lead, between a distal end and a proximal end of the lead;
    • positioning the lead in a catheter, the lead carrying an electrode;
    • deploying the lead from the catheter; and
    • withdrawing the stylet from the lead through the opening by moving the stylet proximally away from the distal end of the lead through the lumen while the lead remains at a spinal modulation site.


41. The method of clause 40, wherein positioning the lead further comprises steering a steerable portion of the lead, the steerable portion comprising the intermediate portion and the distal end of the lead.


42. The method of clause 41, wherein deploying the lead further comprises:

    • moving the stylet into a lumen extending longitudinally between the opening and the distal end of the lead; and
    • positioning the lead with the stylet so that the lead is proximate to a spinal modulation site.


43. The method of clause 42, wherein positioning the lead further comprises moving the steerable portion of the lead relative to a proximal portion of the lead with the stylet.


44. The method of any of clauses 40-43, further comprising preventing the stylet from extending outwardly from a lead body by positioning a lead anchor around a portion of the sidewall carrying the opening.


45. The method of any of clauses 40-44, further comprising delivering electrical modulation signals to the spinal modulation site via the electrode carried by the lead.


46. The method of any of clauses 40-45, further comprising positioning the stylet in the steerable portion of the lead before deploying the lead from the catheter.


47. A method for treating a patient, comprising:

    • withdrawing a stylet from a lead through an opening within a sidewall of the lead arranged at an intermediate portion of the lead.


48. The method of clause 47, wherein withdrawing the stylet includes moving the stylet proximally away from a distal end of the lead through a lead lumen while the lead remains at a modulation site.


49. The method of clause 47, wherein withdrawing the stylet includes moving the stylet distally away from a proximal end of the lead through a lead lumen after inserting the proximal end and the stylet into a pulse generator to electrically connect the lead to the pulse generator.


50. The method of clause 47, further comprising:

    • inserting the stylet into the opening, wherein the intermediate portion is located between a distal end and a proximal end of the lead;
    • positioning the lead in a catheter, the lead carrying an electrode; and
    • deploying the lead from the catheter.


51. The method of clause 47, further comprising;

    • inserting the stylet into the opening, wherein the intermediate portion is located between a proximal end and a distal end of the lead; and
    • inserting the stylet and the proximal end of the lead into a pulse generator.


52. The method of any of clauses 47-51, wherein the lead is an implantable lead.


53. The method of clause 52, wherein the implantable lead is a spinal cord stimulation lead, a deep brain stimulation lead, a peripheral nerve stimulation lead, or a sacral stimulation lead.

Claims
  • 1. A patient therapy device, comprising: a patient-implantable lead having a proximal portion, an intermediate portion and a distal portion, the intermediate portion having a sidewall, the sidewall having an opening extending transverse to a length of the lead, the lead further having at least one electrical contact disposed at at least one of the distal portion or the proximal portion, and a lumen inside of the lead, wherein the lumen extends from at least one of a distal end or a proximal end of the lead at least to the opening; anda stylet having a shaft with a proximal region and a distal region, wherein the distal region of the stylet is sized and shaped to be removably inserted into the lumen through the opening.
  • 2. The patient therapy device of claim 1, wherein the distal region and the distal portion together comprise a distal zone of the device.
  • 3. The patient therapy device of claim 2, wherein the distal zone of the device is generally straight.
  • 4. The patient therapy device of claim 1, wherein the distal portion of the lead is generally straight in a deployed configuration.
  • 5. The patient therapy device of claim 1, wherein the lead has a lead length measured from the proximal end of the lead to the distal end of the lead.
  • 6. The patient therapy device of claim 5, wherein the lead length is selected from the group consisting of about 50 centimeters (cm), about 55 cm, about 60 cm, about 65 cm, about 70 cm, about 75 cm, about 80 cm, about 85 cm, about 90 cm, about 95 cm, and about 100 cm.
  • 7. The patient therapy device of claim 6, wherein the lead has a steerable length extending from the opening to the distal end of the lead.
  • 8. The patient therapy device of claim 7, wherein the steerable length is selected from the group consisting of about 10 cm, about 15 cm, about 20 cm, about 25 cm, about 30 cm, about 35 cm, about 40 cm, about 45 cm, and about 50 cm.
  • 9. The patient therapy device of claim 8, wherein the lead has a lead length selected from the group consisting of about 50 cm, about 60 cm, and about 70 cm, and the lead has a steerable length of about 30 cm.
  • 10. The patient therapy device of claim 1, wherein the lead has a steerable length extending from the opening to the proximal end of the lead.
  • 11. The patient therapy device of claim 10, wherein the steerable length from about 1 cm to about 10 cm.
  • 12. The patient therapy device of claim 11, wherein the steerable length is about 2.5 cm.
  • 13. The patient therapy device of claim 1, wherein the lead is a first lead having a first lead length and a first steerable length extending from the opening of the first lead to the distal end of the first lead and wherein the therapy device further comprises a second lead having a second lead length different than the first lead length, and a second steerable lead length at least approximately the same as the first steerable lead length.
  • 14. The patient therapy device of claim 13, further comprising a third lead having a third lead length different than the first and second lead lengths, and a third steerable lead length at least approximately the same as the first steerable lead length.
  • 15. The patient therapy device of claim 1, wherein the lumen extends longitudinally along a longitudinal axis of the lead between the opening and the at least one of the distal end or the proximal end, and is positioned centrally in the lead, when viewed in a cross-section normal to the longitudinal axis of the lead.
  • 16. The patient therapy device of claim 1, wherein the lumen extends longitudinally along a longitudinal axis of the lead between the opening and the at least one of the distal end or the proximal end, and is positioned off-center in the lead, when viewed in a cross-section normal to the longitudinal axis of the lead.
  • 17. The patient therapy device of claim 1, wherein the intermediate portion of the lead and the at least one of the distal portion or the proximal portion of the lead have a generally circular cross-sectional shape.
  • 18. The patient therapy device of claim 1, wherein the intermediate portion of the lead and the at least one of the distal portion or the proximal portion of the lead have an elliptical cross-sectional shape.
  • 19. The patient therapy device of claim 1, wherein the distal portion and the intermediate portion together have a first stiffness and the proximal portion has a second stiffness greater than the first stiffness.
  • 20. The patient therapy device of claim 1, further comprising a lead anchor coupleable to the lead.
  • 21. The patient therapy device of claim 20, wherein the lead anchor further comprises: a longitudinally extending sleeve having an aperture sized and positioned to receive the lead; anda retainer disposed around the sleeve and operable to compress at least a portion of the sleeve against the lead.
  • 22. The patient therapy device of claim 21, wherein the lead anchor further comprises at least one anchor tab positioned to facilitate attaching the lead anchor to a patient.
  • 23. The patient therapy device of claim 21, wherein the anchor is positioned to engage the intermediate portion of the lead comprising the opening.
  • 24. The patient therapy device of claim 20, wherein the anchor has a stiffness greater than a stiffness of the proximal portion of the lead.
  • 25. The patient therapy device of claim 1, wherein the opening is a first opening and wherein the lead has a second opening disposed in the sidewall of the intermediate portion, the first opening being positioned between the second opening and the distal portion.
  • 26. A spinal cord modulation lead for positioning within a patient and delivering electrical modulation signals to the patient at a treatment site, the lead comprising: at least one electrical contact; anda lead body having; a proximal portion,a distal portion, wherein the at least one electrical contact is disposed at the distal portion,an intermediate portion disposed between the proximal portion and the distal portion,a distal end, wherein the distal end is atraumatic,a sidewall extending longitudinally along a longitudinal axis of the lead body, the sidewall having an opening at the intermediate portion, anda lumen positioned interiorly from the sidewall and extending longitudinally between the distal end and the opening.
  • 27. The lead of claim 26, wherein the opening is sized and shaped to receive a stylet removably insertable into the lumen through the opening.
  • 28. The lead of claim 27, further comprising a membrane penetrable by the stylet and positioned over or within the opening.
  • 29. The lead of claim 28, wherein the membrane includes a plug or a valve.
  • 30. The lead of claim 29, wherein the valve includes a one-way valve.
  • 31. The lead of claim 30, wherein the one-way valve includes a septum valve.
  • 32. The lead of claim 26, wherein the distal portion is generally straight when positioned at the treatment site.
  • 33. The lead of claim 26, wherein the lead has a lead length extending between a proximal end of the lead and the distal end.
  • 34. The lead of claim 33, wherein the lead length is selected from the group consisting of about 50 centimeters (cm), about 55 cm, about 60 cm, about 65 cm, about 70 cm, about 75 cm, about 80 cm, about 85 cm, about 90 cm, about 95 cm, and about 100 cm.
  • 35. The lead of claim 26, wherein the lead has a steerable length extending between the opening and the distal end of the lead.
  • 36. The lead of claim 35, wherein the steerable length is selected from the group consisting of about 10 cm, about 15 cm, about 20 cm, about 25 cm, about 30 cm, about 35 cm, about 40 cm, about 45 cm, and about 50 cm.
  • 37. The lead of claim 26, wherein the lead has a lead length selected from the group consisting of about 50 cm, about 60 cm, and about 70 cm, and the lead has a steerable length of about 30 cm.
  • 38. The lead of claim 26, wherein the distal portion and the intermediate portion together have a first stiffness and the proximal portion has a second stiffness greater than the first stiffness.
  • 39. The lead of any of claim 26, wherein the at least one contact is a first electrical contact and the opening is a first opening, and wherein the lead further comprises a second electrical contact at the proximal portion, and wherein the lead has a second opening in the sidewall, the second opening being between the first opening and a proximal end of the lead, with the lumen extending proximally from the second opening to the proximal end of the lead.
  • 40. A method for treating a patient, comprising: inserting a stylet into an opening within a sidewall of the lead, wherein the opening is located in an intermediate portion of the lead, between a distal end and a proximal end of the lead;positioning the lead in a catheter, the lead carrying an electrode;deploying the lead from the catheter; andwithdrawing the stylet from the lead through the opening by moving the stylet proximally away from the distal end of the lead through the lumen while the lead remains at a spinal modulation site.
  • 41. The method of claim 40, wherein positioning the lead further comprises steering a steerable portion of the lead, the steerable portion comprising the intermediate portion and the distal end of the lead.
  • 42. The method of claim 41, wherein deploying the lead further comprises: moving the stylet into a lumen extending longitudinally between the opening and the distal end of the lead; andpositioning the lead with the stylet so that the lead is proximate to a spinal modulation site.
  • 43. The method of claim 42, wherein positioning the lead further comprises moving the steerable portion of the lead relative to a proximal portion of the lead with the stylet.
  • 44. The method of claim 40, further comprising preventing the stylet from extending outwardly from a lead body by positioning a lead anchor around a portion of the sidewall carrying the opening.
  • 45. The method of claim 40, further comprising delivering electrical modulation signals to the spinal modulation site via the electrode carried by the lead.
  • 46. The method of claim 40, further comprising positioning the stylet in the steerable portion of the lead before deploying the lead from the catheter.
  • 47. A method for treating a patient, comprising: withdrawing a stylet from a lead through an opening within a sidewall of the lead arranged at an intermediate portion of the lead;inserting the stylet into the opening, wherein the intermediate portion is located between a proximal end and a distal end of the lead; andinserting the stylet and the proximal end of the lead into a pulse generator.
  • 48. The method of claim 47, wherein withdrawing the stylet includes moving the stylet proximally away from a distal end of the lead through a lead lumen while the lead remains at a modulation site.
  • 49. The method of claim 47, further comprising: inserting the stylet into the opening;positioning the lead in a catheter, the lead carrying an electrode; anddeploying the lead from the catheter.
  • 50. The method of claim 47, wherein the lead is an implantable lead.
  • 51. The method of claim 50, wherein the implantable lead is a spinal cord stimulation lead, a deep brain stimulation lead, a peripheral nerve stimulation lead, or a sacral stimulation lead.
  • 52. A patient therapy device, comprising: a patient-implantable lead having a proximal portion, an intermediate portion and a distal portion, the intermediate portion having a sidewall, the sidewall having an opening, the lead further having at least one electrical contact disposed at at least one of the distal portion or the proximal portion, and a lumen inside of the lead, wherein the lumen extends longitudinally along a longitudinal axis of the lead between the opening and the at least one of the distal end or the proximal end, and is positioned off-center in the lead, when viewed in a cross-section normal to the longitudinal axis of the lead; anda stylet having a shaft with a proximal region and a distal region, wherein the distal region of the stylet is sized and shaped to be removably inserted into the lumen through the opening.
CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority to U.S. Provisional Application No. 62/650,111, filed on Mar. 29, 2018, and incorporated herein by reference.

US Referenced Citations (738)
Number Name Date Kind
3195540 Waller et al. Jul 1965 A
3724467 Avery et al. Apr 1973 A
3774618 Avery Nov 1973 A
3796221 Hagfors Mar 1974 A
4096866 Fischell Jun 1978 A
4136703 Wittkampf Jan 1979 A
4141365 Fischell et al. Feb 1979 A
4282886 King Aug 1981 A
4285347 Hess Aug 1981 A
4328813 Ray May 1982 A
4355224 Mesick et al. Oct 1982 A
4374527 Iversen Feb 1983 A
4379462 Borkan et al. Apr 1983 A
4383532 Dickhudt May 1983 A
4414986 Dickhudt et al. Nov 1983 A
4422917 Hayfield Dec 1983 A
4432377 Dickhudt Feb 1984 A
4462401 Burgio Jul 1984 A
4462402 Burgio et al. Jul 1984 A
4465079 Dickhudt Aug 1984 A
4466690 Osypka Aug 1984 A
4498482 Williams Feb 1985 A
4515168 Chester et al. May 1985 A
4538624 Tarjan Sep 1985 A
4573448 Kambin Mar 1986 A
4573481 Bullara Mar 1986 A
4579120 MacGregor Apr 1986 A
4603696 Cross, Jr. et al. Aug 1986 A
4658835 Pohndorf Apr 1987 A
4683895 Pohndorf Aug 1987 A
4721551 Byers et al. Jan 1988 A
4744370 Harris May 1988 A
4744371 Harris May 1988 A
4764132 Stutz, Jr. Aug 1988 A
4796642 Harris Jan 1989 A
4830776 Thompson May 1989 A
4898173 Low et al. Feb 1990 A
4919653 Martinez et al. Apr 1990 A
4920979 Bullara May 1990 A
4926878 Snedeker May 1990 A
4934367 Daglow et al. Jun 1990 A
4934383 Glumac Jun 1990 A
4940065 Tanagho et al. Jul 1990 A
4961434 Stypulkowski Oct 1990 A
4979511 Terry, Jr. Dec 1990 A
5000194 van den Honert et al. Mar 1991 A
5007902 Witt Apr 1991 A
5036862 Pohndorf Aug 1991 A
5042486 Pfeiler et al. Aug 1991 A
5046511 Maurer et al. Sep 1991 A
5070605 Daglow Dec 1991 A
5072458 Suzuki Dec 1991 A
5078140 Kwoh Jan 1992 A
5081990 Deletis Jan 1992 A
5121754 Mullett Jun 1992 A
5129404 Spehr et al. Jul 1992 A
5159926 Ljungstroem Nov 1992 A
5179962 Dutcher et al. Jan 1993 A
5190529 McCrory et al. Mar 1993 A
5205297 Montecalvo et al. Apr 1993 A
5211165 Dumoulin et al. May 1993 A
5257636 White Nov 1993 A
5265608 Lee et al. Nov 1993 A
5273053 Pohndorf Dec 1993 A
5306236 Blumenfeld et al. Apr 1994 A
5314458 Najafi et al. May 1994 A
5325873 Hirschi et al. Jul 1994 A
5351394 Weinberg Oct 1994 A
5351687 Kroll et al. Oct 1994 A
5351697 Cheney Oct 1994 A
5354326 Comben et al. Oct 1994 A
5360441 Otten Nov 1994 A
5366489 Burgio et al. Nov 1994 A
5375596 Twiss Dec 1994 A
5392791 Nyman et al. Feb 1995 A
5425367 Shapiro et al. Jun 1995 A
5458629 Baudino et al. Oct 1995 A
5458631 Xavier Oct 1995 A
5464446 Dreessen et al. Nov 1995 A
5480421 Otten Jan 1996 A
5496363 Burgio et al. Mar 1996 A
5527338 Purdy Jun 1996 A
5531778 Maschino et al. Jul 1996 A
5562722 Racz et al. Oct 1996 A
5578074 Mirigian Nov 1996 A
5643330 Holsheimer Jul 1997 A
5669882 Pyles Sep 1997 A
5690117 Gilbert Nov 1997 A
5727553 Saad Mar 1998 A
5728148 Bostrom et al. Mar 1998 A
5730628 Hawkins Mar 1998 A
5755750 Petruska et al. May 1998 A
5759471 Malewicz Jun 1998 A
5760341 Laske et al. Jun 1998 A
5766042 Ries et al. Jun 1998 A
5769877 Barreras, Sr. Jun 1998 A
5843146 Cross, Jr. Dec 1998 A
5843148 Gijsbers Dec 1998 A
5846226 Urmey Dec 1998 A
5848126 Fujita et al. Dec 1998 A
5865843 Baudino Feb 1999 A
5871487 Warner et al. Feb 1999 A
5871531 Struble Feb 1999 A
5895416 Barreras Apr 1999 A
5902236 Iversen May 1999 A
5927277 Baudino et al. Jul 1999 A
5935159 Cross, Jr. et al. Aug 1999 A
5957912 Heitzmann Sep 1999 A
5957965 Moumane et al. Sep 1999 A
5957968 Belden et al. Sep 1999 A
5983126 Wittkampf Nov 1999 A
6042432 Hashizawa Mar 2000 A
6052623 Fenner et al. Apr 2000 A
6055456 Gerber Apr 2000 A
6066165 Racz May 2000 A
6078839 Carson Jun 2000 A
6104960 Duysens Aug 2000 A
6106460 Panescu et al. Aug 2000 A
6125291 Miesel et al. Sep 2000 A
6129742 Wu et al. Oct 2000 A
6134459 Roberts et al. Oct 2000 A
6134477 Knuteson Oct 2000 A
6144866 Miesel et al. Nov 2000 A
6154678 Lauro Nov 2000 A
6161047 King et al. Dec 2000 A
6163727 Errico Dec 2000 A
6175769 Errico et al. Jan 2001 B1
6178357 Gliner et al. Jan 2001 B1
6185463 Baudino Feb 2001 B1
6192278 Werner et al. Feb 2001 B1
6192279 Barreras, Sr. et al. Feb 2001 B1
6198952 Miesel Mar 2001 B1
6198963 Haim et al. Mar 2001 B1
6205356 Holcomb Mar 2001 B1
6205359 Boveja Mar 2001 B1
6205361 Kuzma et al. Mar 2001 B1
6210417 Baudino Apr 2001 B1
6214016 Williams et al. Apr 2001 B1
6216045 Black et al. Apr 2001 B1
6248112 Gambale et al. Jun 2001 B1
6249965 Bullara et al. Jun 2001 B1
6251115 Williams et al. Jun 2001 B1
6263230 Haynor et al. Jul 2001 B1
6273877 West et al. Aug 2001 B1
6292702 King et al. Sep 2001 B1
6296631 Chow Oct 2001 B2
6298265 Burgio Oct 2001 B1
6300359 Flisak et al. Oct 2001 B1
6304785 McCreery et al. Oct 2001 B1
6308103 Gielen Oct 2001 B1
6309401 Redko et al. Oct 2001 B1
6319241 King et al. Nov 2001 B1
6321104 Gielen et al. Nov 2001 B1
6321123 Morris et al. Nov 2001 B1
6364899 Dobak, III Apr 2002 B1
6366815 Haugland et al. Apr 2002 B1
6371943 Racz et al. Apr 2002 B1
6374140 Rise Apr 2002 B1
6393323 Sawan et al. May 2002 B1
6393327 Scribner May 2002 B1
6397108 Camps et al. May 2002 B1
6415187 Kuzma et al. Jul 2002 B1
6429217 Puskas Aug 2002 B1
6438418 Swerdlow et al. Aug 2002 B1
6442435 King et al. Aug 2002 B2
6445955 Michelson et al. Sep 2002 B1
6449511 Mintchev et al. Sep 2002 B1
6451030 Li et al. Sep 2002 B2
6456874 Hafer et al. Sep 2002 B1
6463328 John Oct 2002 B1
6464682 Snoke Oct 2002 B1
6473644 Terry, Jr. et al. Oct 2002 B1
6473653 Schallhorn et al. Oct 2002 B1
6473654 Chinn Oct 2002 B1
6474341 Hunter et al. Nov 2002 B1
6477427 Stolz et al. Nov 2002 B1
6480820 Clopton et al. Nov 2002 B1
6482049 Swearingen Nov 2002 B1
6484059 Gielen et al. Nov 2002 B2
6493590 Wessman et al. Dec 2002 B1
6493592 Leonard et al. Dec 2002 B1
6512949 Combs et al. Jan 2003 B1
6516226 Bishay et al. Feb 2003 B1
6516807 Panescu et al. Feb 2003 B1
6522927 Bishay et al. Feb 2003 B1
6522929 Swing Feb 2003 B2
6522932 Kuzma et al. Feb 2003 B1
6529774 Greene Mar 2003 B1
6540568 Miyazaki Apr 2003 B2
6542774 Hill et al. Apr 2003 B2
6542780 Leonard Apr 2003 B1
6546293 Errico et al. Apr 2003 B2
6549797 Leonard et al. Apr 2003 B1
6549810 Leonard et al. Apr 2003 B1
6549812 Smits Apr 2003 B1
6553264 Redko et al. Apr 2003 B2
6554809 Aves Apr 2003 B2
6556868 Naritoku et al. Apr 2003 B2
6556869 Leonard et al. Apr 2003 B1
6556873 Smits Apr 2003 B1
6560491 Leonard et al. May 2003 B1
6587719 Barrett et al. Jul 2003 B1
6587733 Cross, Jr. et al. Jul 2003 B1
6600956 Maschino et al. Jul 2003 B2
6605094 Mann et al. Aug 2003 B1
6609029 Mann et al. Aug 2003 B1
6622038 Barrett et al. Sep 2003 B2
6622051 Bishay et al. Sep 2003 B1
6704605 Soltis et al. Mar 2004 B2
6714822 King et al. Mar 2004 B2
6718209 Williamson et al. Apr 2004 B2
6718211 Smits Apr 2004 B2
6721604 Robinson et al. Apr 2004 B1
6725096 Chinn et al. Apr 2004 B2
6733500 Kelley et al. May 2004 B2
6735471 Hill et al. May 2004 B2
6741892 Meadows et al. May 2004 B1
6741893 Smits May 2004 B2
6745079 King Jun 2004 B2
6754539 Erickson et al. Jun 2004 B1
6758854 Butler et al. Jul 2004 B1
6805676 Klint Oct 2004 B2
6836687 Kelley et al. Dec 2004 B2
6842647 Griffith et al. Jan 2005 B1
6847845 Belden Jan 2005 B2
6871098 Nuttin et al. Mar 2005 B2
6875571 Crabtree et al. Apr 2005 B2
6895276 Kast et al. May 2005 B2
6895283 Erickson et al. May 2005 B2
6901289 Dahl et al. May 2005 B2
6902547 Aves et al. Jun 2005 B2
6907293 Grill et al. Jun 2005 B2
6907295 Gross et al. Jun 2005 B2
6907299 Han Jun 2005 B2
6909918 Stypulkowski Jun 2005 B2
6929656 Lennox Aug 2005 B1
6934589 Sundquist et al. Aug 2005 B2
6944501 Pless Sep 2005 B1
6961621 Krishnan et al. Nov 2005 B2
6970747 Kokones et al. Nov 2005 B2
6971393 Marno Dec 2005 B1
6980863 van Venrooij et al. Dec 2005 B2
6981314 Black et al. Jan 2006 B2
6993384 Bradley et al. Jan 2006 B2
6993390 Zappala Jan 2006 B2
6999819 Swoyer et al. Feb 2006 B2
6999820 Jordan Feb 2006 B2
7010856 Suda et al. Mar 2006 B2
7020531 Colliou et al. Mar 2006 B1
7022109 Ditto Apr 2006 B1
7047078 Boggs, II et al. May 2006 B2
7047082 Schrom et al. May 2006 B1
7047084 Erickson et al. May 2006 B2
7051419 Schrom et al. May 2006 B2
7069078 Houben Jun 2006 B2
7069083 Finch et al. Jun 2006 B2
7072719 Vinup et al. Jul 2006 B2
7090661 Morris et al. Aug 2006 B2
7107097 Stern et al. Sep 2006 B2
7107104 Keravel et al. Sep 2006 B2
7110827 Sage et al. Sep 2006 B2
7127298 He et al. Oct 2006 B1
7130691 Falci Oct 2006 B2
7130696 Carter et al. Oct 2006 B2
7133722 Hansen et al. Nov 2006 B2
7136695 Pless et al. Nov 2006 B2
7142919 Hine et al. Nov 2006 B2
7145229 Maghribi et al. Dec 2006 B2
7146222 Boling Dec 2006 B2
7146224 King Dec 2006 B2
7149585 Wessman et al. Dec 2006 B2
7153279 Ayad Dec 2006 B2
7153307 Scribner Dec 2006 B2
7162304 Bradley Jan 2007 B1
7164944 Kroll et al. Jan 2007 B1
7164951 Ries et al. Jan 2007 B2
7174213 Pless Feb 2007 B2
7174219 Wahlstrand et al. Feb 2007 B2
7181288 Rezai et al. Feb 2007 B1
7182726 Williams et al. Feb 2007 B2
7182783 Trieu Feb 2007 B2
7184838 Cross, Jr. Feb 2007 B2
7184840 Stolz et al. Feb 2007 B2
7184841 Bodner et al. Feb 2007 B1
7184842 Seifert et al. Feb 2007 B2
7186601 Fukunaga et al. Mar 2007 B2
7187981 Tanaka Mar 2007 B2
7187982 Seifert et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7200443 Faul Apr 2007 B2
7200446 Borkan Apr 2007 B2
7206642 Pardo et al. Apr 2007 B2
7209787 DiLorenzo Apr 2007 B2
7211103 Greenberg et al. May 2007 B2
7212867 Van Venrooij et al. May 2007 B2
7225016 Koh May 2007 B1
7236834 Christopherson et al. Jun 2007 B2
7244150 Brase et al. Jul 2007 B1
7270650 Morris et al. Sep 2007 B2
7282033 Urmey Oct 2007 B2
7299095 Barlow et al. Nov 2007 B1
7340306 Barrett et al. Mar 2008 B2
7363076 Yun et al. Apr 2008 B2
7363089 Vinup et al. Apr 2008 B2
7379776 Chitre et al. May 2008 B1
7383090 O'Brien et al. Jun 2008 B2
7386341 Hafer et al. Jun 2008 B2
7386350 Vilims Jun 2008 B2
7393351 Woloszko et al. Jul 2008 B2
7421297 Giftakis et al. Sep 2008 B2
7425142 Putz Sep 2008 B1
7450992 Cameron Nov 2008 B1
7455666 Purdy Nov 2008 B2
7460913 Kuzma et al. Dec 2008 B2
7463917 Martinez Dec 2008 B2
7486991 Libbus et al. Feb 2009 B2
7493159 Hrdlicka et al. Feb 2009 B2
7496404 Meadows et al. Feb 2009 B2
7499755 Cross, Jr. Mar 2009 B2
7500985 Saadat Mar 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7546164 King Jun 2009 B2
7580753 Kim et al. Aug 2009 B2
7584004 Caparso et al. Sep 2009 B2
7590454 Garabedian et al. Sep 2009 B2
7604644 Schulte et al. Oct 2009 B2
7613516 Cohen et al. Nov 2009 B2
7613524 Jordan Nov 2009 B2
7616988 Stahmann et al. Nov 2009 B2
7617003 Caparso et al. Nov 2009 B2
7617006 Metzler et al. Nov 2009 B2
7623919 Goetz et al. Nov 2009 B2
7627380 Podhajsky et al. Dec 2009 B2
7640064 Swoyer Dec 2009 B2
7672734 Anderson et al. Mar 2010 B2
7684873 Gerber Mar 2010 B2
7689284 Imran et al. Mar 2010 B2
7702379 Avinash et al. Apr 2010 B2
7769441 Foreman et al. Aug 2010 B2
7769442 Shafer Aug 2010 B2
7769472 Gerber Aug 2010 B2
7781806 VanBuskirk et al. Aug 2010 B2
7797057 Harris Sep 2010 B2
7805188 Brushey Sep 2010 B2
7810233 Krulevitch et al. Oct 2010 B2
7810996 Giphart et al. Oct 2010 B1
7829694 Kaemmerer Nov 2010 B2
7831307 Moffitt Nov 2010 B1
7844343 Wahlstrand et al. Nov 2010 B2
7853321 Jaax et al. Dec 2010 B2
7853330 Bradley et al. Dec 2010 B2
7860568 Deininger et al. Dec 2010 B2
7881806 Horrigan et al. Feb 2011 B2
7904149 Gerber Mar 2011 B2
7922738 Eichmann et al. Apr 2011 B2
7996055 Hauck et al. Aug 2011 B2
8000805 Swoyer et al. Aug 2011 B2
8010207 Smits et al. Aug 2011 B2
8014873 Jones et al. Sep 2011 B2
8019439 Kuzma et al. Sep 2011 B2
8019443 Schleicher et al. Sep 2011 B2
8024035 Dobak, III Sep 2011 B2
8036756 Swoyer et al. Oct 2011 B2
8060207 Wallace et al. Nov 2011 B2
8078280 Sage Dec 2011 B2
8123807 Kim Feb 2012 B2
8131357 Bradley Mar 2012 B2
8140172 Jones et al. Mar 2012 B1
8197494 Jaggi et al. Jun 2012 B2
8200343 Gerber et al. Jun 2012 B2
8204569 Gerber et al. Jun 2012 B2
8224459 Pianca et al. Jul 2012 B1
8229573 Chen et al. Jul 2012 B2
8249720 Verzal et al. Aug 2012 B2
8255057 Fang et al. Aug 2012 B2
8301268 Jones et al. Oct 2012 B1
8303502 Washburn et al. Nov 2012 B2
8355791 Moffitt Jan 2013 B2
8355797 Caparso et al. Jan 2013 B2
8412349 Barker Apr 2013 B2
8467883 Chen Jun 2013 B2
8483845 Sage Jul 2013 B2
8494652 Cantlon et al. Jul 2013 B2
8548601 Chinn et al. Oct 2013 B2
8634934 Kokones Jan 2014 B2
8644954 Jaax et al. Feb 2014 B2
8676331 Parker Mar 2014 B2
8731671 Rodby et al. May 2014 B2
8761902 Kulle Jul 2014 B2
8805519 Parker et al. Aug 2014 B2
9026226 Gerber et al. May 2015 B2
9089672 Hendriksen et al. Jul 2015 B2
9138574 Kern et al. Sep 2015 B2
9265935 Thacker Feb 2016 B2
9358388 Parker et al. Jun 2016 B2
9409010 Farhat et al. Aug 2016 B2
9504839 Leven Nov 2016 B2
9510818 Lee Dec 2016 B2
9517332 Olson et al. Dec 2016 B2
9517334 Barner et al. Dec 2016 B2
9687649 Thacker et al. Jan 2017 B2
9889293 Siegel et al. Feb 2018 B2
9987482 Nageri et al. Jun 2018 B2
10016604 Biele et al. Jul 2018 B2
10092744 Sommer et al. Oct 2018 B2
10105536 Orts et al. Oct 2018 B2
20010000800 Partridge et al. May 2001 A1
20010014820 Gielen et al. Aug 2001 A1
20010016765 Gielen et al. Aug 2001 A1
20010023368 Black et al. Sep 2001 A1
20010025192 Gerber et al. Sep 2001 A1
20010027336 Gielen et al. Oct 2001 A1
20010031989 Swing Oct 2001 A1
20010053885 Gielen et al. Dec 2001 A1
20020022872 Gielen et al. Feb 2002 A1
20020022873 Erickson et al. Feb 2002 A1
20020052640 Bigus et al. May 2002 A1
20020072787 Partridge et al. Jun 2002 A1
20020107553 Hill et al. Aug 2002 A1
20020111661 Cross et al. Aug 2002 A1
20020128700 Crass Sep 2002 A1
20020156513 Borkan Oct 2002 A1
20020161417 Scribner Oct 2002 A1
20020173718 Frisch et al. Nov 2002 A1
20020177887 Krebs Nov 2002 A1
20020198568 Hafer et al. Dec 2002 A1
20030018365 Loeb Jan 2003 A1
20030018367 DiLorenzo Jan 2003 A1
20030032997 Pianca et al. Feb 2003 A1
20030055476 Vinup et al. Mar 2003 A1
20030062048 Gradon et al. Apr 2003 A1
20030083697 Baudino et al. May 2003 A1
20030083724 Jog et al. May 2003 A1
20030088245 Woloszko et al. May 2003 A1
20030097165 Krulevitch et al. May 2003 A1
20030097166 Krulevitch et al. May 2003 A1
20030114752 Henderson et al. Jun 2003 A1
20030114895 Gordon et al. Jun 2003 A1
20030120150 Govari Jun 2003 A1
20030136418 Behm Jul 2003 A1
20030187483 Grey et al. Oct 2003 A1
20030199948 Kokones et al. Oct 2003 A1
20030199949 Pardo Oct 2003 A1
20030199951 Pardo et al. Oct 2003 A1
20030199952 Stolz et al. Oct 2003 A1
20030199953 Stolz et al. Oct 2003 A1
20030199962 Struble et al. Oct 2003 A1
20030204206 Padua et al. Oct 2003 A1
20030208247 Spinelli et al. Nov 2003 A1
20030216792 Levin et al. Nov 2003 A1
20030220677 Doan et al. Nov 2003 A1
20030229387 Cross et al. Dec 2003 A1
20030233134 Greenberg et al. Dec 2003 A1
20040015133 Karim Jan 2004 A1
20040015188 Coulter Jan 2004 A1
20040015205 Whitehurst et al. Jan 2004 A1
20040015206 Bishay et al. Jan 2004 A1
20040024428 Barrett et al. Feb 2004 A1
20040024439 Riso Feb 2004 A1
20040024440 Cole Feb 2004 A1
20040087877 Besz et al. May 2004 A1
20040088009 Degroot May 2004 A1
20040088021 Cameron et al. May 2004 A1
20040088033 Smits et al. May 2004 A1
20040088034 Smits et al. May 2004 A1
20040093053 Gerber et al. May 2004 A1
20040097803 Panescu May 2004 A1
20040111139 McCreery Jun 2004 A1
20040122475 Myrick et al. Jun 2004 A1
20040127942 Yomtov et al. Jul 2004 A1
20040138536 Frei et al. Jul 2004 A1
20040152958 Frei et al. Aug 2004 A1
20040162601 Smits Aug 2004 A1
20040172085 Knudson et al. Sep 2004 A1
20040172100 Humayun et al. Sep 2004 A1
20040176683 Whitin et al. Sep 2004 A1
20040186528 Ries et al. Sep 2004 A1
20040186543 King et al. Sep 2004 A1
20040186544 King Sep 2004 A1
20040210290 Omar-Pasha Oct 2004 A1
20040210291 Erickson et al. Oct 2004 A1
20040215301 Lokhoff et al. Oct 2004 A1
20040215305 Sage Oct 2004 A1
20040215307 Michels et al. Oct 2004 A1
20040236387 Fang et al. Nov 2004 A1
20040243206 Tadlock Dec 2004 A1
20040260356 Kara et al. Dec 2004 A1
20050004417 Nelson et al. Jan 2005 A1
20050004638 Cross Jan 2005 A1
20050004639 Erickson Jan 2005 A1
20050010260 Gerber Jan 2005 A1
20050015128 Rezai et al. Jan 2005 A1
20050020970 Gerber Jan 2005 A1
20050021069 Feuer et al. Jan 2005 A1
20050021119 Sage Jan 2005 A1
20050027325 Lahti et al. Feb 2005 A1
20050027338 Hill Feb 2005 A1
20050027339 Schrom et al. Feb 2005 A1
20050027340 Schrom et al. Feb 2005 A1
20050027341 Schrom et al. Feb 2005 A1
20050033371 Sommer et al. Feb 2005 A1
20050049486 Urquhart et al. Mar 2005 A1
20050049648 Cohen et al. Mar 2005 A1
20050049650 Nuttin et al. Mar 2005 A1
20050049663 Harris et al. Mar 2005 A1
20050049664 Harris et al. Mar 2005 A1
20050065588 Zhao et al. Mar 2005 A1
20050070969 Gerber Mar 2005 A1
20050070974 Knudson et al. Mar 2005 A1
20050070982 Heruth et al. Mar 2005 A1
20050070987 Erickson Mar 2005 A1
20050075684 Phillips et al. Apr 2005 A1
20050075702 Shafer Apr 2005 A1
20050075707 Meadows et al. Apr 2005 A1
20050085870 Goroszeniuk Apr 2005 A1
20050090885 Harris et al. Apr 2005 A1
20050096718 Gerber et al. May 2005 A1
20050107753 Rezai et al. May 2005 A1
20050107859 Daglow et al. May 2005 A1
20050107861 Harris et al. May 2005 A1
20050113878 Gerber May 2005 A1
20050119713 Whitehurst et al. Jun 2005 A1
20050131486 Boveja et al. Jun 2005 A1
20050131506 Rezai et al. Jun 2005 A1
20050137648 Cosendai et al. Jun 2005 A1
20050137667 Omar-Pasha et al. Jun 2005 A1
20050137668 Khan Jun 2005 A1
20050138791 Black et al. Jun 2005 A1
20050138792 Black et al. Jun 2005 A1
20050165458 Boveja et al. Jul 2005 A1
20050165465 Pianca et al. Jul 2005 A1
20050171587 Daglow et al. Aug 2005 A1
20050182420 Schulte et al. Aug 2005 A1
20050182421 Schulte et al. Aug 2005 A1
20050182422 Schulte et al. Aug 2005 A1
20050182424 Schulte et al. Aug 2005 A1
20050182425 Schulte et al. Aug 2005 A1
20050187600 Hunter et al. Aug 2005 A1
20050203599 Garabedian et al. Sep 2005 A1
20050209665 Hunter et al. Sep 2005 A1
20050209667 Erickson et al. Sep 2005 A1
20050216070 Boveja et al. Sep 2005 A1
20050222635 Krakovsky Oct 2005 A1
20050222642 Przybyszewski et al. Oct 2005 A1
20050222657 Wahlstrand et al. Oct 2005 A1
20050222658 Hoegh et al. Oct 2005 A1
20050222659 Olsen et al. Oct 2005 A1
20050228221 Hirakawa Oct 2005 A1
20050240229 Whitehurst et al. Oct 2005 A1
20050246003 Black et al. Nov 2005 A1
20050246004 Cameron et al. Nov 2005 A1
20050283216 Pyles Dec 2005 A1
20050288566 Levendusky et al. Dec 2005 A1
20060004429 Mrva et al. Jan 2006 A1
20060025832 O'Keeffe et al. Feb 2006 A1
20060041277 Deem et al. Feb 2006 A1
20060052765 Pyles et al. Mar 2006 A1
20060085070 Kim Apr 2006 A1
20060089691 Kaplan et al. Apr 2006 A1
20060089692 Cross et al. Apr 2006 A1
20060089695 Bolea et al. Apr 2006 A1
20060089696 Olsen et al. Apr 2006 A1
20060089697 Cross et al. Apr 2006 A1
20060106440 Chandran et al. May 2006 A1
20060111768 Wessman et al. May 2006 A1
20060122654 Bradley et al. Jun 2006 A1
20060127158 Olson et al. Jun 2006 A1
20060161236 King Jul 2006 A1
20060167525 King Jul 2006 A1
20060168805 Hegland et al. Aug 2006 A1
20060173262 Hegland et al. Aug 2006 A1
20060200218 Wahlstrand Sep 2006 A1
20060241725 Libbus et al. Oct 2006 A1
20060247569 Bertrand et al. Nov 2006 A1
20060247747 Olsen et al. Nov 2006 A1
20060247748 Wahlstrand et al. Nov 2006 A1
20060247749 Colvin Nov 2006 A1
20060253182 King Nov 2006 A1
20060259095 Wyler et al. Nov 2006 A1
20060259110 Wallace et al. Nov 2006 A1
20060264122 Aman et al. Nov 2006 A1
20060265024 Goetz et al. Nov 2006 A1
20060265037 Kuzma Nov 2006 A1
20060271137 Stanton-Hicks Nov 2006 A1
20070032836 Thrope et al. Feb 2007 A1
20070038052 Swoyer et al. Feb 2007 A1
20070043403 Blamey et al. Feb 2007 A1
20070048289 Grandjean Mar 2007 A1
20070050004 Swoyer et al. Mar 2007 A1
20070050005 Lauro Mar 2007 A1
20070055332 Swoyer Mar 2007 A1
20070088414 Campbell et al. Apr 2007 A1
20070100386 Tronnes et al. May 2007 A1
20070100391 Armstrong May 2007 A1
20070100408 Gerber May 2007 A1
20070106144 Squeri May 2007 A1
20070106289 O'Sullivan May 2007 A1
20070112404 Mann et al. May 2007 A1
20070118198 Prager May 2007 A1
20070135881 Vilims Jun 2007 A1
20070149048 O'Brien et al. Jun 2007 A1
20070150026 Bourget et al. Jun 2007 A1
20070150036 Anderson Jun 2007 A1
20070191709 Swanson Aug 2007 A1
20070191903 Bruinstroop Aug 2007 A1
20070191904 Libbus et al. Aug 2007 A1
20070191909 Ameri et al. Aug 2007 A1
20070203540 Goetz et al. Aug 2007 A1
20070208394 King et al. Sep 2007 A1
20070213795 Bradley et al. Sep 2007 A1
20070249901 Ohline et al. Oct 2007 A1
20070255295 Starkbaum et al. Nov 2007 A1
20070255364 Gerber et al. Nov 2007 A1
20070255365 Gerber et al. Nov 2007 A1
20070255366 Gerber et al. Nov 2007 A1
20070255367 Gerber et al. Nov 2007 A1
20070255370 Bonde et al. Nov 2007 A1
20070255371 Bonde et al. Nov 2007 A1
20070260290 Hara et al. Nov 2007 A1
20070261115 Gerber et al. Nov 2007 A1
20080039738 Dinsmoor et al. Feb 2008 A1
20080058875 Greenberg et al. Mar 2008 A1
20080097475 Jaggi et al. Apr 2008 A1
20080103569 Gerber May 2008 A1
20080103572 Gerber May 2008 A1
20080103573 Gerber May 2008 A1
20080103576 Gerber May 2008 A1
20080103578 Gerber May 2008 A1
20080103579 Gerber May 2008 A1
20080114433 Sage May 2008 A1
20080125833 Bradley et al. May 2008 A1
20080132926 Eichmann et al. Jun 2008 A1
20080140087 Barbagli Jun 2008 A1
20080140152 Imran et al. Jun 2008 A1
20080177339 Bolea et al. Jul 2008 A1
20080183221 Burdulis Jul 2008 A1
20080234791 Arle et al. Sep 2008 A1
20080262430 Anderson et al. Oct 2008 A1
20080275467 Liao et al. Nov 2008 A1
20080300651 Gerber et al. Dec 2008 A1
20080319311 Hamadeh Dec 2008 A1
20090048638 Rey et al. Feb 2009 A1
20090069803 Starkebaum Mar 2009 A1
20090125060 Rivard et al. May 2009 A1
20090132017 Erickson et al. May 2009 A1
20090198306 Goetz et al. Aug 2009 A1
20090204173 Fang et al. Aug 2009 A1
20090204192 Carlton et al. Aug 2009 A1
20090210029 Tsui Aug 2009 A1
20090216306 Barker Aug 2009 A1
20090248118 Bradley Oct 2009 A1
20090259280 Wilkin et al. Oct 2009 A1
20090270940 Deininger et al. Oct 2009 A1
20090299444 Boling Dec 2009 A1
20090319013 Boling et al. Dec 2009 A1
20100069736 Finneran et al. Mar 2010 A1
20100094115 Pond, Jr. et al. Apr 2010 A1
20100094116 Silverstein Apr 2010 A1
20100114283 King May 2010 A1
20100137938 Kishawi Jun 2010 A1
20100137944 Zhu Jun 2010 A1
20100137955 Milijasevic et al. Jun 2010 A1
20100152538 Gleason et al. Jun 2010 A1
20100204569 Burnside et al. Aug 2010 A1
20100211135 Caparso et al. Aug 2010 A1
20100256696 Schleicher et al. Oct 2010 A1
20100267265 Dilmaghanian Oct 2010 A1
20100274312 Alataris et al. Oct 2010 A1
20100274314 Alataris et al. Oct 2010 A1
20100274315 Alataris et al. Oct 2010 A1
20100274316 Alataris et al. Oct 2010 A1
20100274336 Nguyen-Stella et al. Oct 2010 A1
20100280570 Sturm et al. Nov 2010 A1
20100286551 Harlev et al. Nov 2010 A1
20100292769 Brounstein et al. Nov 2010 A1
20100298905 Simon Nov 2010 A1
20100305631 Bradley et al. Dec 2010 A1
20100318165 Harris Dec 2010 A1
20100324414 Harlev et al. Dec 2010 A1
20100324570 Rooney et al. Dec 2010 A1
20110004281 Jones Jan 2011 A1
20110009927 Parker et al. Jan 2011 A1
20110031961 Durand et al. Feb 2011 A1
20110046617 Thompson et al. Feb 2011 A1
20110071593 Parker Mar 2011 A1
20110106052 Chiang et al. May 2011 A1
20110106100 Bischoff May 2011 A1
20110160568 Seeley et al. Jun 2011 A1
20110166582 Syed et al. Jul 2011 A1
20110178573 Nguyen-Stella et al. Jul 2011 A1
20110202097 Bonde et al. Aug 2011 A1
20110224682 Westlund et al. Sep 2011 A1
20110230943 Johnson et al. Sep 2011 A1
20110245903 Schulte et al. Oct 2011 A1
20120083709 Parker et al. Apr 2012 A1
20120083856 Thacker Apr 2012 A1
20120173946 Terry et al. Jul 2012 A1
20120209285 Barker et al. Aug 2012 A1
20120232626 Daglow Sep 2012 A1
20130041445 Erickson et al. Feb 2013 A1
20130066331 Chitre et al. Mar 2013 A1
20130066411 Thacker et al. Mar 2013 A1
20130096642 Wingeier Apr 2013 A1
20130116754 Sharma et al. May 2013 A1
20130138191 Jones May 2013 A1
20130245739 Arber Sep 2013 A1
20130261697 Parker Oct 2013 A1
20130268037 Schulte et al. Oct 2013 A1
20130296957 Tronnes Nov 2013 A1
20140031837 Perryman et al. Jan 2014 A1
20140081362 Wicklund Mar 2014 A1
20140155973 Grigsby et al. Jun 2014 A1
20140180305 Pianca Jun 2014 A1
20140200627 Parker et al. Jul 2014 A1
20140303685 Rosenberg et al. Oct 2014 A1
20140343564 Feler et al. Nov 2014 A1
20140343656 Wechter Nov 2014 A1
20150005859 Thacker et al. Jan 2015 A1
20150012077 Parker et al. Jan 2015 A1
20150141787 Bonde May 2015 A1
20150151114 Black et al. Jun 2015 A1
20150290461 Mln Oct 2015 A1
20160059006 Doan et al. Mar 2016 A1
20160302827 Chitre et al. Oct 2016 A1
20160346553 Black Dec 2016 A1
20160354609 Parker et al. Dec 2016 A1
20160360993 Thacker et al. Dec 2016 A1
20170151428 Schleicher et al. Jun 2017 A1
20170151432 Christopherson et al. Jun 2017 A1
20170189676 Bentley et al. Jul 2017 A1
20170252032 Hiorth et al. Sep 2017 A1
20170281949 Thacker Oct 2017 A1
20180099147 Kane et al. Apr 2018 A1
20180296827 Pianca et al. Oct 2018 A1
20180311494 Wang et al. Nov 2018 A1
20190001122 Ganty et al. Jan 2019 A1
20190105503 Leven Apr 2019 A1
20190308010 Sunkeri et al. Oct 2019 A1
Foreign Referenced Citations (15)
Number Date Country
101920065 Dec 2010 CN
0158316 Oct 1985 EP
2086630 Nov 2010 EP
1477203 Sep 2015 EP
1334745 May 2017 EP
2539016 Nov 2017 EP
2731671 Apr 2019 EP
WO-9003824 Apr 1990 WO
WO-2006045091 Apr 2006 WO
WO-2006055388 May 2006 WO
WO-2008094952 Aug 2008 WO
WO-2009097224 Aug 2009 WO
WO-2009129329 Oct 2009 WO
WO-2011014570 Feb 2011 WO
WO-2014209814 Dec 2014 WO
Non-Patent Literature Citations (7)
Entry
US 6,184,239 B1, 02/2001, Puskas (withdrawn)
Intrel® Model 7490 / 7491 Extensions for Spinal Cord Stimulation (SCS), Medtronic Neuro, Minneapolis, MN 1984, 9 pages.
Kulkarni et al., “A two-layered forward model of tissue for electrical; impedance tomography,” Physiol Meas., 30(6); pp. 1-24, Jun. 2009.
Kumar et al., “Spinal Cord Stimulation in Treatment of Chronic Benign Pain: Challenges in Treatment Planning and Present Status, a 22-Year Experience,” Neurosurgery, vol. 58, No. 3, Mar. 2006, 16 pages.
Medtronic, “Physician and Hospital Staff Manual,” InterStrim System, Neurological Division. 93 pages, undated.
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/024573, Applicant: Nevro Corp., dated Aug. 8, 2019, 10 pages.
Extended European Search Report and Written Opinion for European Patent Application No. 19778392.1, Applicant: Nevro Corp., dated Nov. 5, 2021, 6 pages.
Related Publications (1)
Number Date Country
20190308010 A1 Oct 2019 US
Provisional Applications (1)
Number Date Country
62650111 Mar 2018 US